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ABSTRACT
TECHNOLOGY-DRIVEN HEART FAILURE MANAGEMENT SYSTEM:
CHANGES IN FUNCTIONAL CAPACITY AND QUALITY OF LIFE
Venkata S. Chilakapati
April 14, 2010

Background: Heart failure treatment guidelines emphasize the importance of
daily weight monitoring. To support this practice, the Health Care Financing
Administration Heart Failure Demonstration Project (2000) was designed to evaluate the
effect of technology driven monitoring of daily weight and symptoms in elderly HF
patients (NYHA class II to IV). This sub-study is conducted to assess the effect of a
technology driven HF monitoring system on clinically meaningful change in functional
capacity and quality oflife (QOL).

Methods: This is a randomized, multi-centered, controlled clinical trial in which
Medicare beneficiaries with a history of hospitalization within one year were randomized
to standard care or standard care + a technology driven heart failure monitoring system.
Primary end points were clinically meaningful change in functional capacity [6-minute
walk distance (6MWD) or 6-minute work (6MW)] and QOL [Minnesota Living with
Heart Failure Questionnaire (MLHF)] after 6-months of follow-up. Regression to the
mean effects were estimated and adjusted according to the Edwards-Nunnally (EN)
method. Clinically meaningful change is then defined in terms of the standard error of
measurement (SEM) criterion.
v

Results: Two hundred eighty four patients from three centers in USA were
randomized. Mean age was 74 +/- 9 yrs, 58% were male, 82% were Caucasians, and New
York Heart Association class II (31%), III (59%), and IV (10%). The change in
functional capacity in terms of 6WD was 42 m, by 6MW was 3668 kg/m of work, and
change in QOL in terms ofMLHF total score by 6.0, physical dimension score by 4.0,
and emotional dimension score by 2.0 from baseline. Body mass index, Left ventricular
Ejection Fraction, beta-blocker usage and intra-cardiac device (leD) implantation were
the best clinically relevant predictors of change in functional capacity. Technology
driven heart failure management did not result in a clinically meaningful incremental
benefit in functional capacity or in QOL.

Conclusions: There is no significant clinically meaningful benefit in functional
capacity or in QOL from technology driven HF monitoring system in NYHA class II-IV
elderly HF patients. Further, monitoring HF patients increased outpatient care resource
utilization and costs, and was associated with a significantly poorer QOL.

VI

TABLE OF CONTENTS
PAGE
ACKNOWLEDGEMENTS ............................................................................................... iv
ABSTRACT ........................................................................................................................ v
LIST OF TABLES ........................................................................................................... xiv
LIST OF FIGURES ....................................................................................................... xviii
INTRODUCTION .............................................................................................................. 1
Heart Failure .......................................................................................................... 1
Disease Impact ....................................................................................................... 1
Heart Failure and Clinical Status Changes ............................................................ 3
American Heart Association Prognostic Classification ......................................... 4
Heart Failure and Functional Capacity .................................................................. 5
Heart Failure and Quality Of Life .......................................................................... 6
Heart Failure and Clinical Management ................................................................ 7
Heart Failure and Telemonitoring Systems ........................................................... 9
Telemonitoring Acceptability and Patient Satisfaction ....................................... 10
Observational Studies of Telemonitoring and Hospitalizations and
Readmission Rates ............................................................................................... 11
Randomized Studies of Telemonitoring and Hospitalizations and Mortality ...... 12
Technology-Driven Home Monitoring of Patients With Heart Failure ............... 13
Rationale for the Study ........................................................................................ 13
Significance of the Study ..................................................................................... 15

VB

LITERATURE REVIEW ................................................................................................. 17
Functional Capacity ............................................................................................. 17
Measuring Functional Capacity ........................................................................... 18
6-Minute Walk Test .................................................................................. 18
6-Minute Work .......................................................................................... 21
Quality of Life ...................................................................................................... 22
Definition ...............................................................'.............................................. 22
Measures of Quality of Life ................................................................................. 23
Minnesota Living With Heart Failure Questionnaire ............................... 24
Clinically Meaningful Difference ........................................................................ 25
Definition .................................................................................................. 25
Measuring Clinically Meaningful Difference ........................................... 26
Distribution-Based Approach ................................................................... 26
Anchor-Based Approach ........................................................................... 27
Integration of Distribution- and Anchor-Based Methods ......................... 28
Clinically Meaningful Change in 6-Minute Walk Distance ..................... 30
Clinically Meaningful Change in MLHF Score ........................................ 31
METHODOLOGy ........................................................................................................... 34
Hypotheses ........................................................................................................... 34
Primary Hypothesis 1 ................................................................................ 34
Primary Hypothesis 2 ................................................................................ 34
Secondary Hypothesis 1 ............................................................................ 35
Secondary Hypothesis 2 ............................................................................ 35

Vlll

Study Design ........................................................................................................ 35
Study Setting ........................................................................................................ 36
Eligibility Criteria ................................................................................................ 36
Subject Identification and Enrollment ................................................................. 37
Randomization ..................................................................................................... 39
Intervention .......................................................................................................... 39
Data Collection .................................................................................................... 43
Study Endpoints ................................................................................................... 44
Data Entry ............................................................................................................ 44
Data Quality Monitoring ...................................................................................... 44
Data Management ................................................................................................ 45
Sample Size and Power Calculations ................................................................... 46
Data Analysis ....................................................................................................... 47
Handling of Missing Data ......................................................................... 47
Adjustment for Confounders ..................................................................... 49
Generalizability of Study Sample ............................................................. 49
Preliminary Analyses ................................................................................ 50
Analysis of Endpoints ............................................................................... 51
Adjustment for Regression to the Mean .............................................................. 51
Standard Error of Measurement ........................................................................... 52
Assessment of the Effect of Technology-Driven Heart Failure Management
System .................................................................................................................. 53

IX

RESULTS ......................................................................................................................... 55
Sample Description .............................................................................................. 55
Estimation of Skewness and Kurtosis for Baseline Target Variable
Distribution .......................................................................................................... 61
Comparison of Baseline Characteristics .............................................................. 63
Description of Target Variables After 6 Months ................................................. 63
Correlations Among Changes in Target Variables After 6 Months ..................... 66
Regression to the Mean ........................................................................................ 67
Assessment of Regression to Mean .......................................................... 67
Regression to Mean for Change in 6-Minute Walk Distance Over 6
Months ...................................................................................................... 67
Regression to Mean for Change in 6-Minute Work After 6 Months ........ 69
Regression to Mean for Change in MLHF Score After 6 Months ............ 70
Adjustment of Change in Target Variables From Baseline to 6 Months
to RTM ...................................................................................................... 70
Determination of Clinically Meaningful Change in Target Variables From
Baseline to 6 Months ............................................................................................ 72
Clinically Meaningful Change in 6MWD for Standard Care Vs. TechnologyDriven Disease Management ............................................................................... 74
Clinically Meaningful Change in 6MW From Baseline to 6 Months for
Standard Care Vs. Technology-Driven Disease Management ............................. 77
Clinically Meaningful Change in QOL From Baseline to 6 Months for
Standard Care Vs. Technology-Driven Disease Management ............................. 79

x

Clinically Meaningful Change in Physical Domain Score From Baseline to 6
Months for Standard Care Vs. Technology-Driven Disease Management.. ........ 81
Clinically Meaningful Change in MLHF Emotional Domain Score From
Baseline to 6 Months for Standard Care Vs. Technology-Driven Disease
Management ......................................................................................................... 83
Clinically Meaningful Change in 6MWD to Predict Clinically Meaningful
Similar Directional Change in MLHF Score ....................................................... 85
Clinically Meaningful Change in 6MWD to Predict Clinically Meaningful
Similar Directional Change in MLHF Physical Domain Score ........................... 85
Clinically Meaningful Change in 6MWD to Predict Clinically Meaningful
Similar Directional Change in MLHF Emotional Domain Score ........................ 86
Clinically Meaningful Change in 6MW to Predict Clinically Meaningful
Similar Directional Change in MLHF Score ....................................................... 88
Clinically Meaningful Change in 6MW to Predict Clinically Meaningful
Similar Directional Change in MLHF Physical Domain Score ........................... 89
Clinically Meaningful Change in 6MW to Predict Clinically Meaningful
Similar Directional Change in MLHF Emotional Domain Score ........................ 91
Agreement Between NYHA Class and 6MWD in Assessing the Severity of
Heart Failure ........................................................................................................ 91
Predictors of Clinically Meaningful Change in 6MWD ...................................... 93
Predictors of Clinically Meaningful Change in 6MW ......................................... 96
Predictors for Clinically Meaningful Change in MLHF Total Score ................ 104
Clinical Outcomes ............................................................................................ 108

Xl

Mortality ............................................................................................................. 109
DISCUSSION ................................................................................................................. 113
Summary of Results ........................................................................................... 113
Importance of Clinically Meaningful Change ................................................... 113
Need for Adjustment of Regression to the Mean ............................................... 114
Clinically Meaningful Change in Functional Capacity and Quality of Life ...... 115
Effect of Technology-Driven Heart Failure Management on Functional
Capacity ............................................................................................................. 115
Effect of Technology-Driven Heart Failure Management on Quality of Life ... 116
Effect of Technology-Driven Heart Failure Management on Clinical
Outcomes ........................................................................................................... 116
Agreement Between Objective Assessment of Functional Capacity and
Classification of Heart Failure NYHA Criteria ................................................. 117
Prediction of Change in Quality of Life by Change in Functional Capacity ..... 118
Predictors of Change in Physical and Emotional Dimension Scores by
Change in Functional Capacity .......................................................................... 120
Predictors of Clinically Meaningful Change for Functional Capacity .............. 121
Predictors of Change in Quality of Life ............................................................. 122
Comparison of Existing Studies ........................................................ 122
Strengths of the Study ........................................................................................ 123
Limitations of the Study ..................................................................................... 125
Post-Hoc Power Analysis ................................................................................... 126
Conclusions and Implications ............................................................................ 128

xu

Future Directives for Research .......................................................................... 129
REFERENCES ............................................................................................................... 131
APPENDIX ..................................................................................................................... 157
CURRICULUM VITAE ................................................................................................. 160

X111

LIST OF TABLES
PAGE

TABLE

1. NYHA Functional Classification of Heart Failure ........................................................ 3
2. AHA Prognostic Classification ..................................................................................... 4
3. Tests of Normality for Baseline Target Variables ....................................................... 60
4. Estimated Skewness and Kurtosis ............................................................................... 62
5. Baseline Characteristics .............................................................................................. 64
6. Target Variables After 6 Months for Standard Care vs. Technology-Driven
Management ..................................................................................... 65
7. Mean Change in Functional Capacity and Quality of Life Over 6 Months ................ 66
8. Partial Correlations Between Target Variables at Baseline and Change From
Baseline to 6 Months ................................................................................................... 71
9. Standard Error of Measurement for Target Variables ................................................. 73
10. Standard Error of Measurement for Target Variable After Anchoring by NYHA
Class .............................................................................................. 74
11. Clinically Meaningful Change in 6MWD in Standard Care vs. Technology-Driven
Disease Management. .................................................................................................. 75
12. Clinically Meaningful Change in 6MWD for Standard Care vs. Technology-Driven
Disease Management After Stratification ................................................................... 76
13. Clinically Meaningful Change in 6MW for Standard Care vs. Technology-Driven
Disease Management. .................................................................................................. 77
XIV

14. Clinically Meaningful Change in 6MW for Standard Care vs. Technology-Driven
Disease Management After Stratification ................................................................... 78
15. Clinically Meaningful Change in MLHF Total Score for Standard Care vs.
Technology-Driven Disease Management .................................................................. 79
16. Clinically Meaningful Change in MLHF Total Score for Standard Care vs.
Technology-Driven Disease Management After Stratification ................................... 80
17. Clinically Meaningful Change in MLHF Physical Domain Score for Standard
Care vs. Technology-Driven Disease Management .................................................... 81
18. Clinically Meaningful Change in MLHF Physical Domain Score for Standard
Care vs. Technology-Driven Disease Management After Stratification ..................... 82
19. Clinically Meaningful Change in MLHF Emotional Domain Score for Standard
Care vs. Technology-Driven Disease Management .................................................... 83
20. Clinically Meaningful Change in MLHF Emotional Domain Score for Standard
Care Group vs. Technology-Driven Disease Management After Stratification ......... 84
21. Clinical Meaningful Change in 6MWD vs. Clinically Meaningful Change in
MLHF Total Score ...................................................................................................... 86
22. Clinically Meaningful Change in 6MWD vs. Clinically Meaningful Change in
Physical Dimension Score ........................................................................................... 87
23. Clinically Meaningful Change in 6MWD vs. Clinically Meaningful Change in
Emotional Dimension Score ........................................................................................ 88
24. Clinically Meaningful Change in 6MW vs. Clinically Meaningful Change in
MLHF Score ..................................................................................... 89

xv

25. Clinically Meaningful Change in 6MW vs. Clinically Meaningful Change in
Physical Dimension Score ........................................................................................... 90
26. Clinically Meaningful Change in 6MW vs. Clinically Meaningful Change in
Emotional Dimension Score ........................................................................................ 92
27. Agreement Between NYHA Class and Functional Capacity ...................................... 92
28. Case Processing Summary for Predictors of Clinically Meaningful Change in
6MWD ............................................................................................ 95
29. Model Fitting Information for Predictors of Clinically Meaningful Change in
6MWD ............................................................................................ 96
30. Likelihood Ratio Tests for Predictors of Clinically Meaningful Change in
6MWD ......................................................................................................................... 97
31. Parameter Estimates for Predictors of Clinically Meaningful Change in 6MWD ...... 98
32. Classification Accuracy of Predictors for Clinically Meaningful Change in
6MWD ............................................................................................ 99
33. Case Processing Summary for Predictors of Clinically Meaningful Change in
6MW ............................................................................................. 100
34. Model Fitting Information for Predictors of Clinically Meaningful Change in
6MW ............................................................................................. 101
35. Likelihood Ratio Tests for Predictors of Clinically Meaningful Change in 6MW ... 102
36. Parameter Estimates for Predictors of Clinically Meaningful Change in 6MW ....... 103
37. Classification Accuracy for Predictors of Clinically Meaningful Change in
6MW ............................................................................................. 104

XVI

38. Case Processing Summary for Predictors of Clinically Meaningful Change in
MLHF Total Score .................................................................................................... 106
39. Model Fitting Information for Predictors of Clinically Meaningful Change in
MLHF Total Score .................................................................................................... 106
40. Likelihood Ratio Tests for Predictors of Clinically Meaningful Change in
MLHF Total Score .................................................................................................... 107
41. Parameter Estimates for Predictors of Clinically Meaningful Change in MLHF
Total Score ..................................................................................... 107
42. Classification Accuracy for Predictors of Clinically Meaningful Change in
MLHF Total Score .................................................................................................... 108
43. Clinical End Points for Technology-Driven Management Group vs. Standard
Care Group ..................................................................................... 110

XVll

LIST OF FIGURES
PAGE

FIGURE
1. Adjustment of regression to the mean and calculation of clinically meaningful

change .......................................................................................................................... 53
2. Sample attrition ................................................................................. 56
3. Frequency distribution of 6-minute walk distance at baseline .................................... 57
4. Frequency distribution of 6-minute work at baseline .................................................. 57
5. Frequency distribution ofMLHF scores at baseline ................................................... 58
6. Frequency distribution ofMLHF physical dimension scores at baseline ................... 58
7. Frequency distribution of MLHF emotional dimension scores at baseline ................. 59
8. Scatter plot of change in 6-minute walk distance against baseline ............................. 68
9. Scatter plot of change in 6-minute work against baseline ........................................... 68
10. Scatter plot of change in MLHF total score (QOL) against baseline .......................... 69
11. Kaplan-Meier Curve for Death from all Causes in 6 months ................................... 111

12. Kaplan-Meier Curve for Death from all cardiovascular causes ................................ 111
13. Kaplan-Meier Curve for Death from Heart Failure ................................................... 112

XVlll

CHAPTER I
INTRODUCTION

Heart Failure
Heart failure (HF) is a clinical syndrome in which the cardiac pump fails to pump
an adequate amount of blood to meet systemic requirements, either due to reduced
cardiac contractility (systolic failure) or impaired cardiac relaxation and filling (diastolic
dysfunction) or both (Johnson, Parker, & Patterson, 2002). Initially, HF triggers various
neuro-hormonal mechanisms to compensate. However, as HF progresses, the body's
compensatory and maladaptive mechanisms become imbalanced, which leads to clinical
deterioration (Johnson et aI., 2002). Common signs and symptoms ofHF include fatigue,
shortness of breath, difficulty breathing (especially at night, when lying down, or during
physical exertion), cough, weight gain (from fluid retention), and swelling of the feet and
ankles (National Heart, Lung, and Blood Institute [NHLBI], 2004).
Disease Impact
HF is a major, growing public health problem in the United States affecting 4.9
million people (American Heart Association [AHA], 2009). Each year, 550,000 new
cases are diagnosed (AHA, 2009). The increasing population of older Americans and the
prolongation of the lives of cardiac patients by modem therapeutic strategies have led to
the growing incidence ofHF (Kannel & Belanger, 1991). Among Americans aged 65 or
older, the incidence ofHF is increasing and is approaching 1 in 100 (AHA, 2005, 2009).
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HF accounts for 12 to 15 million U.S. office visits and 6.5 million hospital days
each year, with an average length of stay of 7.7 days for each admission (0' Connell &
Bristow, 1994). Between 1979 and 2005, hospital discharges for HF increased by 157%
(AHA, 2005), and between 1979 and 2009, they rose by 171 % (AHA, 2009). However,
despite advanced therapies and technology, the mortality rate ofHF remains high. The
number of total reported deaths from HF was 287,000 in 1995 and 292,000 in 2005
(AHA, 2009). The overall death rate for HF in 2005 was 52.3 per 100,000 (AHA, 2009).
Moreover, HF is mentioned on the death certificate for one in eight deaths (AHA, 2009).
In spite of the commitment to healthcare in the United States, the economic
burden ofHF is staggering. In 2005, almost 4.8 million Americans were afflicted with
HF, accounting for 15% of the total cost of heart disease (AHA, 2006). In 2005, the total
direct and indirect cost ofHF in the United States was equal to $27.9 billion (AHA,
2005), and the estimated direct and indirect cost for 2009 is $37.2 billion (AHA, 2009).
Almost 75% of costs associated with a typical HF-related hospitalization accumulate
within the first 48 hours (O'Connell & Bristow, 1994). Hospital charges for HF
management are approximately $10,000 per discharge based on a mean length of stay of
5.5 to 6.5 days (AHA, 2008).
According to the Medicare program, Center for Medicare and Medicaid Services
(CMS) expenditures for HF in 1991 were higher than those for cancer and those for
myocardial infarction (Massie & Shah, 1997). HF is the most common Medicare
diagnosis-related group (DRG), and more Medicare dollars are spent on diagnosis and
treatment of HF than on any other diagnosis (Massie & Shah, 1997). HF costs accounted
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for 37% of Medicare spending (AHA, 2008), and in 1999, Medicare reported paying $3.6
billion for care ofHF (AHA, 2005).
Heart Failure and Clinical Status Changes
The severity of HF can be classified symptomatically by using a scheme such as
the New York Heart Association's (NYHA) functional classification, which groups
patients according to the amount of effort needed to produce HF symptoms (Criteria
Committee NHY A, 1964, p. 114; see Table 1).

Table 1
NYHA Functional Classification of Heart Failure

NYHA
grading

Metabolic
equivalenta

Characterisitics

Class I

No limitations. Ordinary physical activity doesn't cause
undue fatigue, dyspnea, or palpitations (asymptomatic LV
dysfunction)

>7

Class II

Slight limitation of physical activity. Ordinary physical
activity results in fatigue, palpitation, dyspnea or angina
pectoris (mild congestive heart failure [CHF])

5

Class III

Marked limitation of physical activity. Less than ordinary
physical activity leads to symptoms (moderate CHF)

2-3

Class IV

Unable to carryon any physical activity without discomfort.
Symptoms of CHF present at rest (severe CHF)

1.6

aMetabolic equivalent is defined as the resting V02 for a 40-year-old 70 kg man. 1 MET
= 3.5 ml 02/minlkg body weight.
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NYHA classification is not a good prognostic indicator, because symptom
severity can rise and fall despite constant pharmacologic and non-pharmacologic
treatments (Hunt, Baker, & Chin, 2001).
American Heart Association Prognostic Classification
The staging system to define the prognosis of patients with HF was developed by
the AHA in 1999 (Hunt et aI., 2001; see Table 2).

Table 2
AHA Prognostic Classification

Stage

Explanation

A

Patients with risk factors for the development of structural heart
disease or for the development of overt HF

B

Presence of structural heart disease (e.g., myocardial infarction or
left ventricular dysfunction) without symptoms of HF

C

Patients with structural heart disease with current or prior symptoms
of HF amenable to therapy

D

HF refractory to conventional treatment requiring ventricular assist
device, transplantation, or palliative care

Note. Prognosis worsens if disease progresses from Stage A through D
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Heart Failure and Functional Capacity
The hallmark of HF is exercise intolerance and activity restriction most
commonly due to impaired breathing and fatigue. These symptoms are debilitating and
result in low functional capacity, progressive physical disability, hospitalization, medical
management, and follow-up. Moreover, as HF advances, functional capacity
deteri orates.
The most popular clinical exercise tests, in order of increasing complexity, are
stair climbing, 6-minute walk test (6MWT), shuttle-walk test, cardiac stress test (e.g.,
Bruce protocol), and cardiopulmonary exercise test (Wasserman, Hansen, Sue, Casaburi,
& Whipp, 1999; Weisman & Zeballos, 1994). A recent review of functional walking

tests concluded that "the 6MWT is easy to administer, better tolerated, and more
reflective of activities of daily living than the other walk tests" (Solway, Brooks, Lacasse,
& Thomas, 2001, p. 256).

The 6MWT is a simple and noninvasive measure of the distance covered in
consecutive 30-meter or 100-foot laps over a 6-minute period (American Thoracic
Society [ATS], 2002). The ability to walk the distance strongly and independently
predicts morbidity and mortality (Bittner et aI., 1993; Guyatt, Sullivan, et aI., 1985;
Lipkin, Scriven, & Poole-Wilson, 1986; Poole-Wilson, 2000). However, distance
covered doesn't take into account differences in bodyweight that are known to influence
exercise capacity (Carter et aI., 2003). Carter et aI. stated that the 6-minute distance
times bodyweight product (6-minute walk work expressed in kilograms per meter of
work) is an improved outcome measure for estimating functional capacity in patients with
chronic obstructive pulmonary disease (COPD; Carter et aI., 2003).

5

Heart Failure and Quality Of Life
Poor physical condition, emotional distress, and frequent hospital admissions
contribute to decreased quality oflife (QOL) among individuals with HF (Blyth et aI.,
1997; Cafagna, Ponte, & Burri 1, 1997), which can lead to social impairments, depression,
and psychological disorders (Majania et aI., 1999; Steptoe, Mohabir, Mahon, &
McKenna, 2000). Depression has been reported in 240/0-42% of patients suffering from
congestive HF (Havranek, Ware, & Lowes, 1999; Skotzko et aI., 2000). Vaccarino et ai.
(2001) and Jiang et ai. (2001) found that depression reduced functional status and
increased readmission rates and mortality in patients with CHF. Depressed patients
required a greater number of inpatient hospital days and at 1 year, showed greater
mortality (Freedland et aI., 1991).
QOL deteriorates more rapidly and seriously for patients with chronic HF than for
those with other chronic disease like arthritis and COPD (Stewart et aI., 1989). Gott et ai.
(2006) investigated the predictors of quality of life in patients with HF and found that
QOL for older people with HF could be described as challenging and difficult. Among
542 people with HF under the age of 60, the following factors were predictive of reduced
QOL: being female, being in an older age group, showing evidence of depression, being
NYHA Class III and IV, having two or more comorbidities, and being from a low
socioeconomic group (Gott et aI., 2006). These factors could help clinicians to identify
those at risk of reduced QOL and appropriately target interventions.
Poor QOL may have a negative effect on compliance with medical treatment and
behavioral regimens (Jaarsma et aI., 1999) and, thus, result in further impairment of
exercise tolerance, prognosis, and QOL. To interrupt this vicious cycle, an integrated and
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comprehensive HF intervention program comprising adequate pharmacologic treatment
and careful home monitoring is needed.
Heart Failure and Clinical Management
The standard of care for HF includes pharmacologic and non-pharmacologic
measures. Pharmacologic management of HF includes diuretics, angiotensin-converting
enzyme (ACE) inhibitors, angiotensin receptor blockers, beta-blockers, digitalis, and
vasodilators. Diuretics, especially loop diuretics (e.g., Furosemide), are used to promote
the elimination of excess sodium and water by the kidneys (Brater, 1997). ACE
inhibitors are recommended for patients with left ventricular dysfunction and have been
shown to reduce mortality from HF; improve HF symptoms, exercise tolerance, and left
ventricular ejection fraction; and reduce emergency room visits and hospitalizations
(Cohn et aI., 1986; Pitt et aI., 1991; Yusuf et aI., 2000).
Angiotensin receptor blockers may be an alternative for patients who are unable
to tolerate ACE inhibitors (Yusuf et ai., 2003). Hydralazine and nitrates in combination
are effective after load and preload reducing agents used in ACE-intolerant patients
(Cohn et ai., 1991). Beta blockers have been shown to slow the progression ofHF and to
reduce hospitalization and mortality by blocking sympathetic stimulation (Hjalmarson et
aI., 2000; Packer et aI., 1999). Digoxin is a weak inotrope, whose main effect is
neuroharmonal modulation; it has been shown to reduce symptoms, improve physical
function and QOL, and decrease the rate of hospitalization in patients with HF, but has
not been shown to have an effect on mortality (Digitalis Investigation Group, 1997).
Inotropic agents like dobutamine or milrinone are useful in select patients with
acute exacerbations of hypotensive HF or shock (Felker et ai., 2001). Spiranolactone, an
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aldosterone antagonist, showed mortality benefit when added to standard therapy for
patients with HF (in NYHA Classes III-IV; Pitt et aI., 1999). Intravenous nitroglycerin
or nitroprusside are recommended for the management of patients with acute pulmonary
edema ("ACC/AHA Guidelines," 2001).
Patients with HF are more prone to sudden cardiac death. Internal cardioverter
defibrillators (lCDs) improve longevity for survivors of cardiac arrest; patients with
sustained ventricular tachycardia, inducible ventricular tachycardia, and left ventricular
ejection fraction (LVEF) less than 30% following a myocardial infarction (Gollob &
Seger, 2002; Moss, Zareba, Hall, Klein, & Wilber, 2002); and dilated cardiomyopathy
patients with LVEF < 30% and NYHA Class II (Kadish et aI., 2004).
Left ventricular assist devices (LV AD) are used for patients with cardiogenic
shock who are unresponsive to inotropic therapy and intra-aortic balloon counter
pulsation, or they may be used as a bridge therapy for patients with cardiac
transplantation (Delgado et aI., 2002; Rose et aI., 2001). Cardiac transplantation is
reserved for otherwise healthy patients with end-stage congestive heart failure (CHF)
with severely impaired function despite optimal medical therapy (Hunt, 1998).
Nonpharmacologic measures include regular exercise for patients with stable HF
(Pina et aI., 2003), restriction of dietary sodium intake, restriction of excess fluid intake,
smoking cessation, restriction of dietary fat intake, abstinence from alcohol and illicit
drugs, and treatment oflipid disorders ("ACC/AHA Guidelines," 2001; NHLBI, 2004).
Despite these measures, the prevalence of chronic HF is increasing, and the situation of
patients with HF will deteriorate unless new management strategies are developed
(Cleland, 2000).

8

The effectiveness of multidisciplinary nonpharmacological approaches for
improving outcomes for patients with HF is under evaluation (McAlister, Stewart, Ferrua,

& McMurray, 2004). Considering the barriers to healthcare access related to funding and
geographic location, development of remote monitoring models for delivering care must
be considered (McAlister et aI., 2004). Remote monitoring models can include
communication technology, such as telemonitoring (transfer of physiological data such as
blood pressure, weight, electrocardiographic (ECG) details, and oxygen saturation
through telephone or digital cable from home to healthcare provider) or regular structured
telephone contacts between patients and healthcare providers, which mayor may not
include the transfer of physiological data (McAlister et aI., 2004).
Heart Failure and Telemonitoring Systems
Telemonitoring permits home monitoring of patients using special telecare
devices in conjunction with a telecommunication system. Telecare is increasingly used
by care providers in various specialties to support chronically ill patients at home using
existing telecommunications systems (Ahring, Ahring, Joyce, & Farid, 1992; Billard et
aI., 1991). Telemonitoring systems can provide diagnostic information, which can be
transmitted manually or automatically, to allow experts to evaluate patients one or more
times per day, or even to continuously monitor them. In view of the rising costs of
hospital care, limitation of functional capacity, and QOL in controlled settings, interest in
telecare has grown, and rapid advances in communication and technology have facilitated
development of patient-friendly telecare equipment (Louis et aI., 2003).
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Telemonitoring Acceptability and Patient Satisfaction
Six observational studies (Deering, Baines, Christianson, & Milner, 2002; de
Lusigman et aI., 2000; de Lusigman, Meredith, Wells, Leatham, & Johnson, 1999; Knox,
Mueller, Vuckovic, & Acker, 2002; Wang, Yu, Chau, & Lamm, 2002; Williams, Keiler,
Sprang, & Mehan, 1998) and one randomized study (Woodend et aI., 2002) assessed
patients' acceptance and compliance with telemonitoring (see also Louis et aI., 2003). De
Lusigman et ai. (1999) measured acceptability and QOL scores while monitoring blood
pressure (BP), heart rate (HR), and weight and video conferencing weekly. De Lusigman
et al. concluded that patients using telemonitoring showed good acceptability and
improved QOL scores after 3 months.
De Lusigman et al. (2000) monitored heart rate, respiratory rate, ECG, and
temperature for a 2-hour period and concluded that telemonitoring had good acceptability
and a reliability of 95%. Deering et al. (2002) monitored weight and symptoms for an
average follow-up of 5.3 months and concluded that telemonitoring improved patient
satisfaction for 94% of patients. Knox et al. (2002) monitored weight, pulse rate, and
symptoms for 8 weeks and found that telemonitoring reduced clinic visits for
optimization of beta-blocker therapy.
Williams et al. (1998) monitored weight and symptoms for 4 months and
concluded that telemonitoring systems showed high compliance and patient satisfaction
in 86% of cases. In a randomized, controlled trial comparing telemonitoring with usual
care, Woodend et al. (2002) found high patient satisfaction and improvement in QOL
through video conferencing with a nurse and telemonitoring of vital signs and ECG.
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Observational Studies of Telemonitoring and Hospitalizations and Readmission Rates
Twelve nonrandomized studies assessed the effect of telemonitoring on
hospitalizations and readmission rates (see also Louis et al. 2003). Shah, Der, Ruggerio,
Heidenrich, and Massie (1998) found a 50% reduction in cardiovascular admissions and
80% acceptability after 8.5 months of patient education, automated reminders, and weight
and blood pressure monitoring for NYHA Class II-IV patients. Cordisco, Beniaminovitz,
Hammond, and Mancini (1999) found reduced emergency room (ER) visits and
hospitalization rates after 12 months of telemonitoring weight and symptoms.
Chrysegolos, Gemme, Coleman, Cheng, & Meyer (1999) monitored weight, BP, and
ECG in NYHA Class III patients for 6 months and concluded that telemonitoring reduced
readmission rates and ER visits. After 12-18 months, telemonitoring of weight, BP, HR,
and O2 saturation led to a significant decrease in the number of admissions and length of
hospital stays in NYHA Class III patients (Bondmass, Malhotra, Castro, & Avitall,
1999).
Heidenrich, Ruggerio, and Massie (1999) monitored weight, BP, and HR and
provided patient education through weekly telephone calls for 7.4 months and found
significantly reduced hospitalizations for NYHA Class II-III patients. Roglieri et al.
(1997) used vital sign monitoring and patient education as an intervention for 3 months
and found reduced 30- and 90-day readmission rates, length of stay, and number of
emergency room visits. Macropoulos and Selna (2002) monitored weight and symptoms
for 12 months and found reduced admissions rates.
Kesinger, Gilani, and Jennison (2002) used electronic home monitoring of weight,
symptoms, and medication compliance for NYHA Class III-IV for 7 months and found a
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50%reduction in hospitalizations. Ertle and Litman (2002) found a 73% reduction in
inpatient costs after 6 months of weight and symptom monitoring. Scalvini, Zanelli,
Volterrani, and Benigno (2002) monitored symptoms and ECG for 12 months and found
a significant reduction in hospitalizations with no difference in mortality compared to a
control group. Lapworth and Dibiase (2000) monitored weight and symptoms ofNYHA
Class III patients for 8 months and found a 75% reduction in hospitalizations and a 47%
reduction in length of hospital stay.
Randomized Studies of Telemonitoring and Hospitalizations and Mortality
Five randomized studies assessed the effect oftelemonitoring on hospitalizations
and mortality rates. Bondmass, Benatar, Castro, and Avitall (2001) found that
telemonitoring weight, HR, BP, and 02 saturation resulted in fewer readmissions and
reduced length of hospital stay for a group of telemonitored patients, compared to a group
of patients given nurse care visits. Jerant, Azari, and Nesbitt (2001) performed two-way
video conferencing integrated with an electronic stethoscope for 6 months with NYHA
Class II patients and found an 86% reduction in readmission charges and an 84%
reduction in the telemonitored group.
Goldberg et al. (2002) telemonitored weight and symptoms ofNYHA Class 111IV patients for 6 months and found no difference in readmission rates compared to

patients receiving standard care; however, there was a significant reduction in mortality
for women under age 65. Johnson, Wheeler, Deuser, and Sousa (2000) found no
difference in cost of healthcare after 10-12 months for patients who used video
consultation with a nurse and patients who received standard care. Massie, West, Van
Ostaeyen, and Salbalvaro (2001) found no significant difference in outcomes between
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groups that did and did not receive telephonic monitoring of weight vital signs and
symptoms.
Technology-Driven Home Monitoring of Patients With Heart Failure
The Health Care Financing Administration (HCF A) Heart Failure Demonstration
Project Study Group of 2000 conducted a trial to assess the impact of a technology-driven
HF home monitoring system on clinical and economic outcomes of Medicare
beneficiaries who were recently hospitalized for HF. The study was conducted in
Billings, Montana (rural); Louisville, Kentucky; and Philadelphia, Pennsylvania. Study
subjects were randomized and received either standard HF care (as described above) or
standard HF care supplemented by home telemonitoring.
The purpose ofthis sub study is to (a) evaluate the effect of home telemonitoring
systems on functional capacity (6-minute walk distance [6MWD] and 6-minute work
[6MW]) and QOL (QOL score); (b) determine clinically meaningful difference in
6MWD or 6MW and Minnesota Living With Heart Failure (MLHF) scores; and (c)
determine the correlation between clinically meaningful differences in 6MWD or 6MW
and QOL (MLHF score) in patients with chronic HF.
Rationale for the Study
Congestive heart failure (CHF) is a major health problem with increasing
incidence and a poor prognosis. It is often accompanied by multiple comorbidities,
disability, depression, and cognitive impairment and leads to deterioration in functional
capacity and QOL (Stott, 2002; Wielenga et aI., 1997). Efforts must be made to develop
novel strategies to reduce the rising cost of care for patients with HF without
compromising the standard of care.
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Louis et al. (2003) conducted a systematic review of telemonitoring studies and
concluded that telemonitoring might have an important role as part of a strategy for
delivery of healthcare for patients with HF. Several multidisciplinary programs and
remote monitoring models were evaluated for effectiveness in terms of a statistically
significant difference in outcomes, but none of the studies made definitive conclusions
about the clinical significance of such strategies for improving outcomes like functional
capacity and QOL (Louis et al., 2003). Thus, integration of technology-driven HF
monitoring into standard care and assessing its impact in terms of clinically significant
improvement in QOL and functional capacity is imperative to designing sound
multidisciplinary disease management models.
Because of the complexity and cost associated with implementing many disease
management programs for patients with HF, there is a need for a simpler, less personnelintensive, more cost-effective approach to the longitudinal care of these patients. Despite
the high prevalence of HF, there have been very few studies of the impact of CHF on
functional capacity and QOL, suggesting the need for epidemiological studies on
functional capacity and QOL (Davis et al., 1999).
In the context of preventive and therapeutic cardiology, functional capacity and
QOL are important outcome measures for evaluating the effectiveness oftreatment
strategies and the course of a disease (Bullinger, 1997; Wenger, 1989). Therefore,
functional capacity and QOL are major goals in the context of preventive and therapeutic
cardiology. It is, therefore, imperative to test the impact of technology-driven therapeutic
modalities ofHF management on functional capacity and QOL of patients with CHF.
With increased rates of patient adherence, compliance, and acceptance of telemonitoring
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technology to monitor HF symptoms (Capomolla, Pinna, La Rovere, Maestri, & Ceresa,
2004; de Lusigman et al., 1999,2000), various investigators are in the process of
developing and evaluating several telemonitoring systems. For example, the HCF A
Demonstration Project Study Group investigated the effectiveness of a technology-driven
home te1emonitoring system for Medicare beneficiaries with chronic HF.
Significance of the Study
The purpose of this study is to evaluate the effect of a technology-driven home
telemonitoring system on functional capacity using 6MWD or 6MW and on QOL using
MLHF. Small differences in functional capacity and QOL may be statistically significant
but clinically unimportant. Therefore, it is necessary to determine the smallest difference
considered worthwhile or clinically important (Hays & Woolley, 2000). The purpose of
this study is to determine clinically meaningful differences in the 6MWD or 6MW and
MLHF scores of patients with chronic HF.
The MLHF scale is superior and more responsive to changes in QOL compared to
the Chronic Heart Failure Questionnaire (CHQ) and the General Health Survey Short
Form 12 and 36 (SF-12 and SF-36) instruments (Bennet et al., 2002; Ni, Toy, Burgess, &
Wise, 2000). Therefore, the purpose of this study is to determine changes in MLHF
scores that are indicative of clinically meaningful change in the QOL of patients with HF.
In a randomized control study, Guyatt, Townsend, Keller, Singer, and Nogradi
(1991) concluded that 6MWD better correlated with formal measures of QOL for patients
with chronic lung disease. Carter et al. (2003) stated that 6-minute distance times
bodyweight product (6MW expressed in kilograms per meter) was an improved outcome
measure to estimate the functional capacity of COPD patients. The purpose of this study
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is to determine the relationship between clinically meaningful change in 6MWD or 6MW
and MLHF scores of patients with CHF.

16

CHAPTER II
LITERATURE REVIEW

CHF is a major health problem with increasing incidence and a poor prognosis. It
is often accompanied by multiple comorbidities, disability, depression, and cognitive
impairment and leads to deterioration in functional capacity and QOL (Stott, 2002;
Wielenga et aI., 1997). Therefore, functional capacity and QOL should be included as
important outcome measures when developing disease management models for patients
with HF. Davis et aI. (1999) stated that there was a lack of data on the effect of disease
monitoring systems on functional capacity and QOL for patients with HF.
Functional Capacity
Functional capacity refers to the performance of, or the capacity to perform,
regular daily activities (Leidy, 1994). Such activities require the integrated efforts of the
heart, lungs, and circulation to deliver oxygen to the metabolically active muscle mass to
perform work (Gibbons et aI., 1997). The capacity of an individual to perform work is
defined by the maximal oxygen consumption (V02 max), the product of cardiac output
(CO), and arteriovenous oxygen (AV0 2) difference at exhaustion (Rowell, 1988).
Functional capacity is often expressed in metabolic equivalents (METs); 1 MET
represents resting energy expenditure, which is approximately 3.5 mL O2 . kg- l . min- l
(Fleg & Lakatta, 1988; Rowell, 1988). Functional capacity is affected by age, sex, the
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presence of disease, and medications that affect aerobic exercise (Fleg & Lakatta, 1988;
Pollock et aI., 1998).
Measuring Functional Capacity
In the hospital setting, functional capacity can be directly measured by
determining V02 max or can be estimated using the highest treadmill or stationary cycle
ergo meter work rate achieved (Jerome et al., 2000). Peak oxygen uptake (peak V02) is a
reference parameter, or gold standard, in the assessment of functional capacity of patients
with HF; however, the procedure for measuring peak oxygen uptake is complex,
invasive, and expensive. Outside the hospital setting, the most widely used methods for
assessing functional capacity, the 6MWT and shuttle walk test, are simple, noninvasive,
and inexpensive. For the 6MWT, patients are instructed to walk as far as they can in 6
minutes. In the shuttle walk test, patients are pressured to meet multiple deadlines
through audio cassette beeps. The 6MWT is self-paced and less likely than the shuttle
walk test to push patients beyond their endurance or through angina or other pain (Paul,
2003).
6-Minute Walk Test
The 6MWT is a practical, simple test that requires a 100-foot hallway but no
exercise equipment or advanced technician training. The test measures the distance that a
patient can quickly walk on a flat, hard surface in a period of 6 minutes, known as the
6MWD. Functional capacity, or exercise capacity, is determined by the integrated
response of multiple systems, including the pulmonary, cardiovascular, hematopoietic,
neuromuscular, and metabolic (ATS, 2002). The 6MWT does not provide specific

18

information on the function of each organ and system involved in the exercise
mechanism; instead, it serves as a surrogate estimate of the collective mechanism.
Most activities of daily living are performed at a sub maximal level. The selfpaced 6MWT assesses the sub maximal level of functional capacity. Often, patients do
not achieve maximum exercise capacity during the 6MWT; instead, they choose their
own intensity of exercise and are allowed to stop and rest during the test (ATS, 2002).
The test has been shown to be useful in assessing prognosis and exercise capacity in
several studies (Bittner et aI., 1993; Cahlin, Mathier, Semigran, Dec, & Disavo, 1996;
Guyatt, Thompson, et al., 1985; Roul, Germain, & Bareiss, 1998; Zugck et al., 1998). In
clinical practice, the 6MWT is used for measuring the response to medical interventions
for patients with moderate to severe heart or lung disease (ATS, 2002).
There is a moderate correlation between distance walked during the 6MWT and
peak V0 2 (L= 0.70), P < .001) and close correlation between distance walked during the
shuttle walk test and peak V0 2 (L= 0.83, P < .001; Morales et aI., 1999). Solway et aI.
(2001) performed a qualitative review of measurement properties of the shuttle walk test
and 6MWT and concluded that exercise performed during the shuttle walk test was
similar to a symptom-limited, maximal, incremental treadmill test. The shuttle walk test
is more difficult to administer, requires more equipment, and is less reflective of activities
of daily living (ATS, 2002; Solway et al., 2001). The 6MWT is easy to administer, better
tolerated, and more reflective of activities of daily living. Therefore, currently, the
6MWT is the test of choice when administering a functional walk test for clinical or
research purposes (ATS, 2002; Solway et aI., 2001).
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As a test of submaximum exercise capacity with high validity and minimal
potential for cardiovascular problems (Demers et ai., 2001), the 6MWT mimics daily
activity (Solway et ai., 2001) and is more relevant to both doctor and patient than the
maximum exercise test (ATS, 2002). Demers et al. (2001) investigated the reliability,
validity, and responsiveness of the 6MWT for patients with HF and concluded that the
6MWT was highly reproducible (intraclass correlation coefficient [ICC] = 0.90),
moderately and inversely correlated to NYHA functional class (L= -0.43,:Q = 0.001), and
weakly inversely correlated to cumulative QOL (MLHF score; L= -0.26,:Q = 0.0001).
In an observational study, O'Keffe, Lye, Donnellan, and Carmichael (1998)
concluded that the 6MWD was more responsive to deterioration than improvement of HF
symptoms. There are several factors that influence the 6MWT: a shorter 6MWD may be
associated with shorter height (short legs), older age, greater body weight, female gender,
impaired cognition, shorter walking corridor (more turns), acute or chronic lung diseases,
cardiovascular diseases, chronic degenerative diseases, and musculoskeletal injuries or
deformities (Paul, 2003). Factors associated with a longer 6MWD are taller height
(longer legs), male gender, high motivation, and medications increasing aerobic exercise.
The effect of these factors must be considered when drawing conclusions about
functional capacity. The strongest indication of the 6MWT is for measuring the response
to medical interventions of patients with moderate to severe heart or lung disease (AT A,
2002). The 6MWT has also been used as a measure of functional status of patients as
well as a predictor of morbidity and mortality (ATS, 2002).
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6-Minute Work
Distance covered during the 6MWT doesn't take into account differences in
bodyweight that are known to influence exercise capacity. Chuang, Lin, and Wasserman
(2001) investigated the calculation of the product of bodyweight and walking distance as
an alternative method for assessing functional capacity. This calculation accounts for
bodyweight differences, and estimates work and energy expenditure through the formula
Force x Distance (Chuang et aI., 2001). Carter et ai. (2003) stated that 6MWD (in
meters) x bodyweight (in kilograms), or 6MW expressed in kilograms per meter of work,
was an improved outcome measure to estimate functional capacity for COPD patients.
For COPD patients, 6MW yielded higher correlation coefficients than 6MWD
when correlated with pulmonary function indices, including lung diffusion for alveolar
ventilation, DLco (L= 0.6 vs. 0.46,.Q...= 0.0001), forced expiratory volume in one minute
(L= 0.52 vs. 0.38,12 = 0.0001), forced vital capacity (L= 0.48 vs. 0.38,12 = 0.0001), vital

capacity (L= 0.48 vs. 0.40,12 = 0.0001), and cycle ergometry gas exchange indices,
including work (in watts; L = 0.79 vs. 0.59,12 = 0.0001), peak oxygen uptake (L= 0.81 vs.
0.54,12= 0.0001), peak minute ventilation (0.59 vs. 0.46,12 = 0.0001), and peak tidal
volume (L= 0.57 vs. 0.43,12 = 0.0001). The ROC curve demonstrated that 6MW had a
significantly larger calculated area under the curve (0.782 vs. 0.708,12 < 0.05) than
6MWD (Carter et aI., 2003).
The pathophysiology ofHF is entirely different from that of CO PD. Functional
capacity of patients with HF is determined by degree of debilitation from frequent
decompensation. Fluctuations in weight may be very rapid and unpredictable. However,
the applicability and correlation of 6MW to HF indices has not been evaluated. Even if a
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statistically significant difference exists between correlation coefficients and the area
under the curves of 6MWD and 6MW, the clinical significance of those differences has
not been determined.
Quality of Life
Definition
The World Health Organization (WHO, 1946) defined health as "a state of
complete physical, mental, and social well-being and not merely the absence of disease or
infirmity". Health status is typically used to represent the patient's subjective (or
perceived) appraisal of his or her state of physical and mental health (Revicki et al.,
2000). The concept of QOL lacks clarity and uniform definition. Health status,
functional status, and QOL are three concepts often used interchangeably when referring
to health.
Gill and Feinstein (1994) stated that QOL incorporates patient values, judgments,
and preferences and that these are subjective experiences, states, and perceptions of one's
overall well-being, including aspects of the physical, psychological, social, economic,
and political environment (Revicki et al., 2000). Guyatt (1993) used the term healthrelated QOL (HRQOL) because many widely valued aspects of life, such as income,
freedom, and quality of the environment, are not generally considered health-related.
Testa and Simonson (1996) defined HRQOL as the "physical, psychological and
social domains of health, seen as distinct areas that are influenced by a person's
experiences, beliefs, expectations and perceptions" (p. 835). QOL is a broad term that
comprises subjective domains as assessed by patients-physical functioning,
psychological functioning, and social functioning-and objective domains as assessed by
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healthcare and social support personnel and measured by laboratory or diagnostic testspsychophatology (CID-IO/DSM-IV-TR), socioeconomic status, and social support (Rui
et al., 2005). Therefore, the goals of disease management for patients with chronic HF
should be directed at improving symptoms, stabilization or improvement in functional
abilities, and improved comfort for the duration of life (Wenger, 1989).
F or asymptomatic patients with HF, the management strategies should aim to
improve ventricular function in order to improve long-term survival and eliminate
interference with QOL, which will improve compliance and enhance long-term outcome
advantages (Wenger, 1989). Majania et al. (1999) found that subjective domains were
highly correlated with a global sense of well-being, and objective domains were less
correlated with a global sense of well-being. QOL reflects subjective perceptions of
harmony within the body and between a patient and the external world (Katsching, 1997).
Measures of Quality of Life
Measures of QOL fall into two categories: (a) generic measures, which attempt to
provide a summary of a patient's perceived QOL, and (b) disease-specific measures,
which focus on problems associated with particular disease states and patient groups
(Guyatt, 1993). Generic measures can be standardized and applied to a wide variety of
illnesses to allow for comparisons (Dempster & Donnelly, 2000). Early QOL research
used psychological well-being scales, including the Affect Balance Scale by Bradburn
(1969), the Quality of Well-Being Scale by Kaplan and Anderson (1988), and the
Psychological General Well-Being Index by Dupuy (1984). Later research included the
Sickness Impact Profile by Gilson et al. (1975); the Nottingham Health Profile by Hunt et
al. (1980) and the Rand SF-36 Health Status Profile by Ware et al. (1993).
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Generic measures lack the range, sensitivity, and flexibility to deal with a
particular illness (Dempster et aI., 2000). Therefore, disease-specific QOL instruments
were developed. Disease-specific instruments are more responsive and more sensitive to
changes (Spertus, Winder, Dewhurst, Deyo, & Stephan, 1994). Some examples of
disease-specific instruments to measure QOL in patients with HF are the Chronic Heart
Failure Questionnaire (Guyatt et aI., 1989), the Minnesota Living with Heart Failure
Questionnaire (Rector, Kubo, & Cohn, 1992), and the Kansas City Cardiomyopathy
Questionnaire (Green, Porter, Bresnahan, & Spertus, 2000).
Although numerous instruments are available to measure QOL, the most
commonly used instruments in HF research are generic instruments (SF-12 and SF-36)
and disease-specific instruments (CHQ and MLHF). Bennett et ai. (2002) conducted a
study to compare the psychometric properties of these instruments and concluded that all
instruments were reliable and valid; however, CHQ and MLHF were more sensitive and
responsive to changing conditions than generic measures were. Considering the
feasibility of administering these instruments and their responsiveness to changes in
QOL, MLHF is superior to CHQ, SF-12, and SF-36 (Bennet et aI., 2002; Ni et aI., 2000).
Minnesota Living With Heart Failure Questionnaire
The MLHF questionnaire is a disease-specific instrument designed to measure the
effects ofHF and treatments for HF on QOL (Rector et aI., 1992). It is composed of21
items and three subscales measuring the following dimensions: (a) the physical
functioning dimension (eight items), (b) the emotional functioning dimension (five
items), and (c) an overall QOL score (all 21 items). Eight separate items not assessing an
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underlying construct or dimension ofHQOL measure social and economic impairment
for patients due to HF and are part of the overall score.
To measure the effects of symptoms, functional limitations, and psychological
distress on an individual's QOL, the MLHF questionnaire asks each person to indicate
using a 6-point Likert scale (0 to 5) to what extent each of the 21 facets prevent them
from living as they desire. The questionnaire results in a total score between 0 (no
impairment) and 105 (severe impairment), which represents the physical, socioeconomic,
and psychological impairments of HF that affect QOL.
Factor analysis identifies two components on the questionnaire-physical and
emotional. The associations between patients' overall ratings of how much HF prevented
them from living as they wanted (r...= 0.8, 2 < 0.01) and their NYHA classification (r...=
0.60,2< 0.01) suggest that the MLHF score is a valid representation of patient
impairment (Rector et aI., 1992). The test-retest reliability of the MLHF score was r...=
0.93 (2 < 0.001) for the total score, r...= 0.89 ill < 0.001) for the physical dimension
subscore, and r...= 0.88

ill < 0.001) for the emotional dimension subscore (Rector &

Cohn,

1992).
Clinically Meaningful Difference
Definition
Jaeschke, Singer, and Guyatt (1989) defined minimal important difference as
the smallest difference in score in the domain of interest which patients perceive
as beneficial and which would mandate, in the absence of troublesome sideeffects and excessive cost, a change in the patient's management. (p. 407)
Small numerical differences in mean scores might give statistically significant
results when large sample sizes are used, but statistical significance is not equivalent to
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clinical significance (Osoba et aI., 1998). Currently, there are no guidelines or standards
to help physicians determine whether or not the treatment provided to patients with CHF
results in a clinically meaningful change in their functional capacity and QOL. The
purpose of this study is to define the level of change in functional capacity (measured by
6MWD or 6MW) and QOL (measured by MLHF) that is clinically meaningful for
patients with CHF.
Measuring Clinically Meaningful Difference
There are two approaches for determining meaningful change: (a) the distribution
based-approach and (b) the anchor-based approach.
Distribution-Based Approach
Distribution-based approaches to determining clinically meaningful change are
based on the statistical characteristics of the obtained sample. To estimate the effect size
(Cohen, 1988; Kazis et aI., 1989) or standard error of measurement (SEM; McHorney &
Tarlov, 1995; Wyrwich, Tierney, & Wolinsky 1999), distribution-based methods use the
empirical distribution of a measure and its psychometric characteristics. Therefore,
distribution-based methods rely only on statistical and psychometric properties of a
measure.
Distribution-based measures fall under three broad categories. First, measures
based on statistical significance evaluate change in relation to the probability that change
occurred by random variation. Examples are paired !-statistic (Husted et aI., 2000) and
growth curve analyses (Speer & Greenbaum, 1995). Second, measures based on sample
variation evaluate change in relation to sample variation. Some examples are effect size
(Cohen, 1988; Kazis, Anderson, & Meenan, 1989), standardized response mean (Stucki
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et aI., 1995), and responsiveness statistic (Guyatt, Bombardier, & Tugwell, 1986). The
final category of measures includes those based on the measurement precision of the
instrument. Some examples are SEM (Wywich et al. 1999) and reliable change index
(Jacobson & Truax, 1991).
According to Crosby, Kolotkin, and Williams (2003),
the most promising distribution-based measures for establishing clinically
meaningful change are those based on the measurement precision of the
instrument (Standard Error of Measurement, SEM and Reliable Change Index,
RCI). Because these measures quantify the amount of error inherent in the
instrument and the amount of random variation that can be expected in repeated
administrations. In addition, they are not influenced to a large degree by
variability in the sample at baseline (as is the effect size), variability of the
observed change (as are the Standardized Response Mean, SRM and the
Responsiveness Statistic), or the sample size (as are the !-statistic and growth
curve analysis). These precision measures can be used to establish cutoffs based
on a desired confidence level. (p. 400)
Anchor-Based Approach
Anchor-based methods define a clinical standard for comparison using the
patient's or physician's perception of change as an external anchor to estimate the clinical
meaningfulness of corresponding change (Jaeschke et al., 1989). Anchor-based
approaches have been used to determine clinically meaningful change via cross-sectional
and longitudinal methods. Various cross-sectional methods described in the literature
include comparison to disease-related criteria (Deyo et al., 1992; Johnson, Goldman, &
Orav, 1995), comparison to non-disease-related criteria (Testa & Lenderking, 1992; Testa
& Simonson, 1996), preference ratings (Llewellyn-Thomas, 1996) and comparison to

known populations (Jacobson & Truax, 1991).
One of the limitations of cross-sectional comparisons is that groups are likely to
differ in many relevant variables besides HRQOL. Samsa et al. (1999) suggested
statistically controlling these variables using regression methods and calculating effect
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sizes based on adjusted mean differences. The most commonly used anchor-based
approaches for establishing clinically meaningful change in longitudinal studies focus on
global ratings of change (Jaeschke et aI., 1989; Stucki et aI., 1995), prediction of
prognosis of future events (Mossey & Shapiro, 1982), and changes in disease-related
outcomes (Kolotkin, Crosby, & Williams, 2002).
According to Crosby et al. (2003),
Longitudinal anchor-based methods are more directly linked with change when
compared to cross-sectional methods because the former are more directly linked
with change. Hence longitudinal anchor-based methods are preferable to crosssectional methods. In considering these longitudinal methods, patient global
ratings are especially well suited for assessing patient's perception of change and
are recommended for that purpose. However, when using global ratings, it is
important to assess the reliability of these ratings. Clinician global ratings and
longitudinal disease-related measures of outcome are the most suitable methods of
determining meaningful change from the clinical perspective. (p. 399)
Integration of Distribution- and Anchor-Based Methods
It's not clear whether it is better to use anchor-based or distribution-based
methods for determining clinically meaningful change. There have been some attempts
to integrate anchor- and distribution-based approaches. Jacobson and Truax (1991)
proposed that individuals should be considered improved or deteriorated only when they
meet both the anchor- and distribution-based criteria for change. Another study by Cella
et al. (2002) to determine clinically meaningful change on the Functional Assessment of
Cancer Therapy-Lung (FACT -L) questionnaire described that clinically meaningful
change determined by anchor-based methods (e.g., differences between clinically
distinguishable groups) was confirmed by distribution-based methods (e.g., effect size,
SEM). The agreement across these methods was high, with kappa ranging from 0.71 to
1.0. Individuals with the greatest impairments at baseline have the greatest opportunity
for improvement compared to individuals with less extreme scores.
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Failure to take RTM (RTM) into account may lead to erroneously concluding that
those with severe impairments have shown clinically meaningful improvement, when
much of that change is due to R TM (Barnett, VanDer Pol, & Dobson, 2005). Cella et al.
(2002), Guyatt and Jaeschke (1997), Hays and Woolley (2000), Juniper, Guyatt, Willan,
and Griffith (1994), and Ware et al. (1993) reported that when a patient is improving, a
smaller amount of change may be considered clinically important than when the patient
worsening. Therefore, direction of change should be accounted for when defining
clinically meaningful change.
Kolotkin et al. (2002) described a method to determine clinically meaningful
change in obesity-specific QOL using the combined information from anchor-based
(weight loss) and distribution-based (SEM corrected for RTM) methods, taking into
account baseline impairment and direction of change. Speer (1992) mentioned that while
defining clinically meaningful difference, if regression to the mean is not present, then
the Jacobson and Truax (1991) method is more appropriate.
Jacobson and Truax (1991) proposed a two-step method. The first step is to
define cutoff points that separate a functional population from a dysfunctional population.
For example, Cutoff A specifies the functional population as those with post-therapy
scores that are two standard deviations (SDs) or more from the pretreatment mean. The
second step compares individual's change from pre- to post-therapy to the standard error
(SE) of measurement of the outcome (± 1.96 SE), referred to as reliable change index
(RCI).
These two steps classify individuals into four categories: recovered (individual
has passed Cutoff A and RCI in the positive direction), improved (passed RCI in the
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positive direction but not Cutoff A), unchanged (passed neither criterion), or deteriorated
(passed RCI in the negative direction). IfRTM is present, the Edwards-NUlU1ally (EN)
method is more appropriate than the Jacobson and Truax method (Edwards et aI., 1978).
The EN method addresses regression to the mean by shrinking pretherapy scores toward
the pretherapy mean using the reliability of the measure. The estimated true score is then
placed at the center of a confidence interval so that estimates can be made of the
significance of post-therapy change, or two SEs from the adjusted center.
Crosby, Kolotkin, and Williams (2004) designed an integrated method that
combined information from anchor- and distribution-based methods using data
aggregated from weight-loss studies. A total of 1,476 weight-loss study participants were
evaluated at baseline and at 6 months using the Impact of Weight on Quality of Life-Lite
(IWQOL-Lite). Then, Crosby et al. used the EN method and corrected SEM for
regression to the mean.
Clinically Meaningful Change in 6-Minute Walk Distance
Using distribution-based methods, G. Claire, Martin, Joseph, Tamiza, and
Stephen (2005) conducted a study of pulmonary hypertension patients to explore
minimally important difference (MID) for 6MWD and SF-36 domains. They concluded
the MID for 6MWD was 39 m, and for SF-36, the MID for physical functioning was 11
m; role physical, 21; social functioning, 16; and vitality, 13.
Redelmier, Bayoumi, Goldstein, and Guyatt (1997) conducted a study of patients
with chronic lung disease and found that the 6MW was significantly correlated with
patients' ratings of their walking ability relative to other patients (L= 0.59,95%
confidence interval [CI]: 0.54 to 0.63). Distances must differ by 54 m for the average
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patient to stop rating themselves as about the same and start rating themselves as either f!
little bit better or a little bit worse (95% CI: 37 to 71 m).
Cooper (2001) conducted a study of patients with chronic pulmonary disease and
considered a 54-meter change in 6MWD to be clinically meaningful based on the
conclusions of Redelmier et al. (1997). Perera, Mody, Woodman, and Studenski (2006)
conducted a secondary analysis of data from an observational study and clinical trials of
community-dwelling older adults and subacute stroke survivors. Perera et al. calculated
the effect size using distribution-based methods (Cohen, 1988; Kazis et aI., 1989; Testa,
1987) and concluded that small meaningful change in 6MWD was 20 m and substantial
change was 50 m. In these trials, RTM and reliability of the instrument were not taken
into account when defining meaningful change in 6MWD.
Clinically Meaningful Change in MLHF Score
According to Rector (2005), clinically meaningful refers to an effect that would
prompt patients and physicians to consider using a treatment if the risk and costs were
acceptable. So far, there has been no gold standard to determine cutoff values for
changes in QOL in terms of improvement or deterioration. Rector et aI. (1995) found
that an improvement of 5 points in the MLHF score was sufficient to be clinically
effective for a majority of patients to take a medication that had no side effects or costs.
According to Bennet et al. (2002), a change of 5 points was the minimum clinically
meaningful change based on the mean change in the MLHF score observed in a group of
patients who rated their change in overall condition as ± 2 or ± 3 on a -7 to +7 scale.
Cohen (1988) provided benchmarks to serve as a guide for interpreting effect size,
where effect size = (mean at baseline - mean at follow-up )/standard deviation at baseline.
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For small effects, the benchmark was 0.2; for moderate effects, 0.5; and for large effects,
0.8. Based on a comprehensive review of the literature, an effect size of 0.2 should serve
as an appropriate definition of the minimum clinically important difference (Samsa et aI.,
1999). Using effect size calculations, conclusions of clinically meaningful change at the
individual level may be influenced by the heterogeneity of the sample. In addition, the
effect size doesn't take into account the variability of change, the test-retest reliability of
the instrument, and R TM.
Wyrwich, Nienaber, et al. (1999) suggested that a change of 1 SEM was clinically
meaningful. The I-SEM (baseline) threshold is equivalent to 0.71 SEM change, and
approximately 52% of the area under the normal curve is between Z = -0.71 and Z = 0.71
(Wyrwich, Nienaber, et al. 1999). To decide if an improvement or deterioration has
occurred at the individual level, a 51 % level of certainty may be applied (Donaldson &
Moinpour,2002). A higher level of certainty (90%-95%) is needed to compare
statistically significant differences at the group level but not at the individual level.
Therefore, at the individual level, change over time exceeding these limits of the ± SEM
baseline are likely to reflect a minimum important change rather than merely
demonstrating measurement error or trivial fluctuations of chronic disease measures
(Wyrwich, Nienaber, et aI., 1999).
SEM is an estimate of error for use in interpreting individual test scores. A test
score is an estimate of a person's true test performance. Using a reliability coefficient
and the test's SD, this value may be calculated as follows:
SEM = SD*[" (1 - r)]

(1)
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Where SD = the standard deviation for the test, and r = the reliability coefficient
for the test.
The higher a test's reliability coefficient, the smaller the test's SEM is. The larger
the SEM, the less reliable the test is. There are no studies that define clinically
meaningful change in MLHF score using clinical anchors such as functional capacity or
NYHA class.

33

CHAPTER III
METHODOLOGY

Hypotheses
F or patients previously hospitalized with HF and with continued symptoms of HF,
addition of technology-driven HF management to standard care may be associated with
clinically meaningful effects when compared to standard medical care alone.
Primary Hypothesis 1
Research hypothesis: Technology-driven HF management is associated with
clinically meaningful effect on functional capacity measured in terms of 6MWD or 6MW
after 6-months follow-up in elderly patients with HF
Null hypothesis: Technology-driven HF management is not associated with
clinically meaningful effect on functional capacity measured in terms of 6MWD or 6MW
after 6-months follow-up in elderly patients with HF.
Primary Hypothesis 2
Research hypothesis: Technology-driven HF management is associated with
clinically meaningful effect on QOL measured in terms ofMLHF score after 6-month
follow-up in elderly patients with HF
Null hypothesis: Technology-driven HF management is not associated with
clinically meaningful effect on QOL measured in terms of MLHF score after 6-month
follow-up in elderly patients with HF.
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Secondary Hypothesis 1
Research hypothesis: There is a correlation between clinically meaningful change
in functional and the QOL in elderly patients with HF after 6-months follow-up.
Null hypothesis: There was no correlation between clinically meaningful change
in functional capacity and the QOL in elderly patients with HF after 6-months follow-up.
Secondary Hypothesis 2
Research hypothesis: Clinically meaningful change in QOL is responsive to
clinically meaningful change in functional capacity after 6-months follow-up in elderly
patients with HF.
Null hypothesis: Clinically meaningful change in QOL is not responsive to
clinically meaningful change in functional capacity after 6-months follow-up in elderly
patients with HF.
Study Design
The HCF A Demonstration Project Study Group designed a randomized trial for
adding a home telemonitoring system to the standard of care for Medicare beneficiaries
with a primary diagnosis of chronic HF and with continued HF symptoms and who were
discharged from an acute care hospital within the previous 6 months. The study was
designed to assess the incremental effect of adding a home telemonitoring system to
standard care on health outcomes, resource utilization, and costs and processes of care for
patients with HF.
Subjects were enrolled and randomized between January 2001 and January 2003.
To examine whether the initial effectiveness oftelemonitoring system would persist or
decay over time, a novel method of randomization was implemented. Six months after
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initial randomization and follow-up, subjects who had been randomly assigned to follow
a home monitoring system were1erandomized to either continue with the home
telemonitoring system or standard care alone. Both groups were followed for an
additional 6 months.
The end points of the HCF A study included cardiovascular rehospitalization or
cardiovascular death within 6 months following study randomization. The secondary end
points explored potential continued benefit and attenuation of benefit over 12 months
after randomization. Using the HF demonstration project data from the HCF A
Demonstration Project Study Group, the effect of adding technology-driven HF
management to standard care on functional capacity (assessed using 6MWD or 6MW)
and QOL (assessed using MLHF score) for patients with chronic HF was assessed in this
sub-study. The purpose of this study was to determine the clinically meaningful change
in 6MWD or 6MW and QOL (MLHF scores) and to explore the correlation among these
variables (if any).
Study Setting
Participants for the main study were recruited from the followings sites: St.
Vincent's Hospital and Health Center in Billings, Montana; Jewish Hospital University of
Louisville School of Medicine in Louisville, Kentucky; and University of Pennsylvania
Health System, Philadelphia, Pennsylvania.
Eligibility Criteria
Participants must be Medicare beneficiaries aged 65 years or older who were
discharged from an acute care hospital with a primary diagnosis ofHF (DRG 127) within
the preceding 6 months. The following criteria also had to be met: (a) evidence ofHF
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(left ventricular ejection fraction < 50% documented on echocardiography, radionuclide
ventriculography, or cardiac catheterization) and currently experiencing symptoms of HF;
(b) ability to stand for 20 s without holding the wall; (c) bodyweight less than 400
pounds; (d) ability to speak English or Spanish (required for the use of the home
telemonitoring system); (e) ability to complete a 6MWT; (f) ability to provide witnessed,
written informed consent for all aspects of the study, including permission to provide or
access the clinical, health status, and medical service utilization data required by the
study protocol prior to enrollment and randomization.
The following subjects were excluded from the study: (a) those participating in
other ongoing HF research or demonstration studies or having prior experience with the
Alere DayLink Monitoring System; (b) those lacking a phone line or accessible phone
jack in the home, as required by the home telemonitoring system; (c) Medicare managed
care participants; (d) patients with chronic dialysis, a serum creatinine level over 3.0 in
the past 30 days, and anticipated initiation of dialysis within 6 months; (e) patients who
had a heart transplant; (f) patients with uncorrected thyroid disease; and (g) patients with
end-stage or terminal illness such as metastatic malignancy or AIDS with anticipated life
expectancy less than 6 months in addition to HF, or a score less than or equal to 25 on a
minimental status exam.
Subject Identification and Enrollment
At each study site, clinical research coordinators (CRCs) identified physicians
who were interested in recruiting patients for the study. After obtaining patients'
permission, CRCs reviewed current and past admission records. All personnel had
HIP AA training and strictly adhered to HIPAA procedures. Patients hospitalized with a

37

primary diagnosis of HF who were Medicare beneficiaries aged 65 or older were
identified. After reviewing their hospital records, CRCs identified potentially eligible
discharged patients who had been recently hospitalized. After screening eligible patients,
CRCs contacted attending physicians to confirm eligibility and obtain the attending
physician's consent to recruit the potential participants.
After confirming eligibility and obtaining the attending physician's consent,
CRCs contacted potential participants by phone and explained the study. Patients who
expressed interest were scheduled for a baseline visit within 2 weeks to obtain written,
signed, dated, and witnessed informed consent, at which time the data coordination center
(DCC) was contacted to begin the randomization process and baseline data collection.
Upon enrollment, the following procedures were performed.
1. Study coordinators obtained the results of MUGA, ECHO, or angiography, if
performed, from the past year. If such a test had not been performed, the
study coordinator requested the physician prescribe one to be completed
within 6 weeks of enrollment, especially to assess ejection fraction.
2. Study coordinators obtained demographic data, medical history, medications,
physician assessment data at baseline (screening visit), and baseline
laboratory data including serum sodium, creatinine, blood urea nitrogen
(BUN), total bilirubin, potassium, digoxin trough level, and ECG results. If
laboratory data were not available, they were obtained within 2 weeks of
baseline visit.
3. Patients completed a baseline 6MWT, and study coordinators documented the
results.
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4. Patients completed QOL questionnaires with the assistance ofthe
coordinators.
5. Study coordinators provided participants with HF diaries and educational
material, explained the importance of self-monitoring and daily recording of
weight in the HF dairy, emphasized the importance of bringing the diary to
each physician visit, and scheduled a 6-month follow-up visit.
Randomization
Eligible subjects who provided written informed consent were randomized using a
1: 1 ratio to the control group (standard HF care) or the intervention group (standard HF
care plus home telemonitoring). Randomization was performed at each site to control
practice-site-specific bias or confounding effects. Randomization was performed prior to
collection of baseline data as soon as eligibility was confirmed to avoid selection bias.
Each enrolled participant was assigned a unique randomization number and unique study
number. These numbers were maintained in a central log at the DCC. All enrollment
and randomization logs were maintained by local CRCs.
Intervention
The HCF A HF Demonstration Project Study Group replicated as much standard
medical care as possible among participants. Therefore, standard HF care was provided
as background therapy for participants in both groups. The only difference between the
two study groups was the addition of a technology-driven HF home telemonitoring
system to the standard of care for the intervention group.
The Alere DayLink Monitoring System was chosen for this study because Alere
was the first company to offer in-home telemonitoring and the system was used in the
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Weight Monitoring in Heart Failure (WHARF) trial (Goldberg et aI., 2002). Upon
completion of the randomization process, the study coordinator faxed patient
demographics, history, and medications at the time of enrollment to Alere Medical Inc.
At the time ofthe study, Alere was licensed to do business in California and had its
corporate headquarters in San Francisco with satellite centers in 25 U.S. states. It
supported more than 30,000 patients, and its call center was staffed with trained
personnel 7 days a week, 365 days a year, from 7:00 a.m. to 5:00 p.m. Pacific Standard
Time.
After receiving patients' information, Alere shipped the devices on the same day
so that patients would receive them the next day at their homes. Installation of the device
was simple, and instructions were mailed to participants along with the devices. By
following instructions, participants connected the three color-coded cables to the required
jacks. After the unit was connected to a power source, the set-up was completed
automatically. The black box (console) prompted participants throughout the installation
process by instructing them to press yes or no keys on the console. By following the
prompts, the patient or family member could complete the set-up. After completing the
set-up, the device was ready to use.
Per protocol, twice daily, the console visibly and audibly prompted participants to
step onto a scale for weighing. After recording their weight, the console compared
patients' weight to the preset weight, or dry weight. Then the console prompted
participants to answer several preset questions. After answering the last question, the
console acknowledged the patient with a thank you and automatically transmitted the
information over the phone line to the telemonitoring station.
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Call center nurses performed twice-daily monitoring (morning and afternoon) of
patients' weight and symptoms using the data transmitted through the telemonitoring
system. When a patient's weight was acceptable and the patient was not symptomatic,
monitoring continued without changes to therapy, and a summary report was sent to the
appropriate physician's office. If a patient's weight was not within an acceptable range
(i.e., it increased by more than 3-5 pounds in 2 days), the patient did not weigh in, or the
patient was symptomatic, call center nurses called the patient or a nurse practitioner to
alert them to the situation. The call center nurses would obtain further information from
the patient and adjust the medical therapy or suggest an ER visit or hospital admission.
In addition to periodic assessments, the intervention group participants received
health education through weekly telephone calls from call center nurses. The nurses
placed special emphasis on medication changes, changes in health status or condition,
and the need for lifestyle modifications. Patients' physicians selected the telemonitoring
and therapy parameters per individual patients' clinical status.
All enrolled participants received standardized HF education and teaching
materials irrespective of whether they were randomized to standard HF care or standard
HF care plus telemonitoring. All patients received a comprehensive educational
handbook, instructions about HF from registered nurses, and a diary with standardized
instructions to record daily weight and symptoms.
Per study protocol, participants were required to attend a follow-up visit at 6
months for data collection for primary and secondary endpoints and for rerandomization.
Participants were also required to attend a follow-up visit at 12 months for data collection
for tertiary endpoints. At the 6-month protocol visit, after data collection, participants
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who used the telemonitoring System were then rerandomized to continue telemonitoring
or to standard care. If the participant was rerandomized to standard care therapy, he or
she was provided with a digital home scale and instructed to obtain and record daily
weight and HF symptoms in a diary.
Due to the nature of the intervention, the intervention group was not blinded.
This might have introduced some bias into the trial; however, the study group agreed that
the design would maximize consistent HF baseline care for every patient independent of
randomization, which would allow the group to determine the true clinical effect of
telemonitoring.
To minimize bias, research staff was blinded to the study hypothesis and group
assignment. They obtained all data through the telephone (details are described in the
Data Collection section). Similarly, event adjudication was determined by a clinical
endpoint committee, which was blinded to the study group.
Group 1: Standard Care
Group 1 participants received a CHF standard care plan individualized through
routine patient care provided by a primary care physician or cardiologist or both. Patients
were given diaries to chart their daily weight and instructed to take the diary with them to
each physician visit.
Group 2: Standard Care Plus Technology-Driven HF Monitoring
In addition to receiving the same CHF standard care that Group 1 received, Group
2 participants were given a telemonitoring System to monitor their weight and symptoms
daily through telephonic transmission of data. The data were used to alert caregivers or
physicians and to reinforce HF management.
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Data Collection
All data were collected through standardized procedures and data collection
instruments. Data coordination was perfonned at the Center for Epidemiology and
Clinical Investigation Sciences, University of Louisville, under the direction of Dr.
Carlton Hornung. CRCs at each site collected baseline data and administered the 6MWT
at the time of enrollment and at 6 and 12 months after enrollment. Regardless of group,
the patients were contacted every 6 weeks (i.e., at study weeks 6, 12, 18,30,36, and 42)
by telephone to obtain supplemental data on social support assessment and any ER visits
or hospitalizations.
At 12 weeks and 36 weeks, additional data on QOL were collected through
completion ofQOL questionnaires via telephone. Research staff who were blinded to the
study hypotheses and the intervention group participants, collected all of the telephone
survey data. The data collected included socio-demographic variables; social and family
support; clinical status; physical, functional, and mental health status; subjective health
rating; HRQOL; and satisfaction with care. After each telephonic contact, research
assistants mailed additional diaries and a self-addressed stamped envelope to participants.
After completion of 6 and 12 month protocol visits, research assistants reminded
participants to return the diaries in the self-addressed envelope. Medicare utilization data
were obtained through CMS service utilization files.
The study endpoints were measured through standardized instruments used in
earlier and ongoing studies, as mentioned in chapter 2. Functional capacity was assessed
using the 6MWT. QOL for patients with chronic HF was measured using the MLHF
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questionnaire. Social support assessment was performed using the Krause-Marchetti
survey.
Study Endpoints
This sub-study was limited to a 6-month follow-up. The purpose ofthe sub-study
was to evaluate the impact of adding telemonitoring to standard care on functional
capacity (in terms of6MWD or 6MW) and QOL (MLHF score) at the study end point.
Data Entry
The HCF A HF Demonstration Project Study Group designed a customized
computer-based system for data entry. The DCC created a separate database for each site
with separate data entry files. Each site had access to its own data entry files but did not
have access to the files at other sites. The site-specific CRCs collected and entered the
data into electronic case report forms during each patient visit and telephone survey.
CRC data transmissions were stored in a temporary database, and integrity of the
data was verified against source documents using the quality assurance keys developed
by the DCC. Separate and secure databases were created on a server at each site and
were password protected; only authorized personnel had access to the data. The DCC
prepared a standard manual of operations to guide CRCs and each clinical site monitoring
team in order to maintain the quality and integrity of the data.
Data Quality Monitoring
Prior to the first month of study, standardized pre-study training sessions were
held at the University of Pennsylvania for the principal investigators (PIs) and CRCs
from all sites. These sessions were to train PIs and CRCs in all aspects of study protocol,
methods, data collection, and data entry. The first line of data quality monitoring was
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performed at the point of data collection. The second line was performed at the time of
data entry. Only after completion of all pre-specified data fields were the files merged
into a site-specific database.
The computer data entry system had a built-in data quality/integrity check system,
which verified the integrity and quality of the data at each site. The DCC maintained an
800-number telephone hotline for CRCs to call with any questions with regard to data
entry or editing. The DCC, project manager, and CRCs had weekly conference calls to
identify and address data collection and quality problems. The director and the DCC
conducted periodic reviews of the collected data and monitored the type and frequency of
data entry errors, edits, and changes at each site.
The DCC merged the electronic case report forms, telemonitoring System data,
and CMS data for each site separately and created individual and site-specific data files
for monitoring the quality of data and tracking of errors at each site. If a high error rate
occurred at any site, notices were sent to the clinical site monitoring team and CRCs.
The integrity of the data was verified with source documents, and errors were rectified at
each site.
Data Management
The data coordination center was located in the Center for Epidemiology and
Clinical Investigation Sciences at the University of Louisville (one of the sites of the
project). The center had PhD-trained biostatisticians, epidemiologists, database
management experts, a web master, and supporting personnel. Database management
experts merged the data from individual sites and prepared a master data file for analysis.

Sample Size and Power Calculations
In the initial protocol, power analysis calculations were perfonned based on the
primary end point of reduction in hospital admission rates.

It was estimated that 175 patients per ann will be needed for the 6 month data
collection period for a primary analysis, a total of 35% patients to detect a 40%
reduction in cardiovascular hospital admission rates (two-sided alpha of 0.05,
80% power, assuming a 6-month readmission rate for the control group
(Krumholz 1997) of 35% and 21 % in the interventional ann. Assuming the 20%
reduction in the sample size during the first 6 months, it was estimated that 220
patients per ann, for total of 440 participants who meet all eligibility criteria and
consent to enroll in the study. (HCF A Heart Failure Demonstration Project, 2000)
According to a recent review published by ATS (2002), optimal reference
equations for healthy population-based samples using standardized 6MWT methods were
not yet available. Miyamoto et ai. (2000) conducted a study in which the median 6MWD
was approximately 580 m for 117 healthy men and 500 m for 173 healthy women.
Another study reported a mean 6MWD of 630 m in 51 healthy older participants (Stevens
et aI., 1999).
Cardiac rehabilitation in patients with various heart diseases increased the 6MWD
by a mean of 170 m, or 15% (Bittner et aI., 1993). In an observational study of 45 older
patients with HF, the smallest difference in 6MWD that was associated with a noticeable
difference in the global rate of worsening was a mean of 43 m (O'Keffe et aI., 1998).
However, there have not been any studies in the literature that defined the degree of
change in 6MWD or 6MW and QOL from a baseline to the point of measurement and
that should be considered clinically meaningful or as demonstrating clinically significant
improvement or deterioration. Also, no randomized studies have found any correlation
between clinically meaningful improvement or deterioration in 6MWD or 6MWW
correlated with and clinically meaningful improvement or deterioration in QOL.
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The focus of this sub-study is to define clinically meaningful cutoffs and use
those cutoffs to estimate the efficacy of technology-driven HF management systems in
improving the functional capacity and QOL for patients with chronic HF. Given
extremely uncertain estimates of the cutoff values for the study variables, it is not
possible to offer a specific power calculation. After obtaining the data, a post-hoc power
analysis may be performed. As the intervention is not invasive and carries no risk,
according to the available data (as mentioned in chapter 2), there is no clinical rationale
to say that the telephonic management of patients with HF is inferior to standard care.
Data Analysis
SPSS version 17.0 soft ware was used for the data analysis. The primary analysis
included all randomized patients using the principle of intent to treat (International
Conference on Harmonization of Technical Requirement for Registration of
Pharmaceuticals for Human Use, 1999). The randomized patients were excluded only
upon objective detection of violation of eligibility criteria. In addition, the subset of
participants who complied with the protocol were analyzed; compliance was determined
by completion of at least 1 month of care under the treatment to which the participant was
randomized, availability of the primary outcome, and absence of any major protocol
violation.
Handling of Missing Data
Individual missing items can be a nuisance to statistical packages based on the
assumption that balanced data are available. If records are deleted where individual items
are missing, there may be both loss of power and bias in estimation. The reasons for
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missing covariate data (e.g., refusal, problems with data collection, rehospitalization, and
death) have been documented.
Many statistical methods may be used to estimate or impute the most likely values
for the missing items. If a patient died prior to the assessment or was hospitalized and
not available for assessment, then 0 m was assigned for 6MWD; however, some ofthe
patients who were hospitalized with CHF exacerbation were able to walk 0 to 25 feet (510 m), which was considered significant impairment in functional capacity. Therefore,
these patients were classified as members of a clinically meaningful deterioration in
functional capacity group.
The MLHF questionnaire consists of 21 items and three subscales measuring the
following dimensions: (a) the physical function dimension (eight items), (b) the
emotional function dimension (five items), and (c) an overall QOL score (all 21 items).
Eight separate items not assessing an underlying construct or dimension of HQOL
measure social and economic impairments for patients due to HF and are part of the
overall score. To measure the effects of symptoms, functional limitations, and
psychological distress on an individual's QOL, the MLHF questionnaire asks participants
to indicate to what extent each of 21 facets prevented them from living as they desired
using a 6-point (0 to 5) Likert scale.
The MLHF questionnaire results in a total score between 0 (no impairment) and
105 (severe impairment), which represents the physical, socioeconomic, and
psychological impairments that affect QOL. The 6-point score is divided into three
quartiles: The scores 0 and I belong to the first quartile (mild impairment); 2 and 3, the
second quartile (moderate impairment); and 4 and 5, the third quartile (severe

48

impairment). For each question, a score of 5 was assigned to those patients who died
prior to assessment, and a score of 4 was assigned to those patients who were hospitalized
and not available for assessment. In both cases, the patients were classified into a
clinically significant deteriorated group.
If a participant filled in most of the questions on the MLHF questionnaire except
for a few (not more than three), then the missing data were estimated using the multiple
means imputation method (Curran et aI., 1998). The objective of imputation is to replace
the missing data with estimated values to preserve the relationships between items and to
reflect, to the extent possible, the most likely true value. The dropouts that were
unrelated to outcomes were ignored in the analysis (Heyting, Tolboom, & Essers, 1992).
Adjustment for Confounders
Although participants were randomly assigned to intervention and control groups,
there was a possibility of unequal distribution of patients due to potential confounders.
Adjustment for covariates associated with the outcome is essential (Altman & Dore,
1991; Hauck, Anderson, & Marcus, 1998; Senn, 1994). Therefore, baseline variables that
were correlated with outcomes were included in multivariable models in the comparison
of two groups.
Potential variables are socio-demographic factors (age, gender, race/ethnicity,
education); heart failure severity and case mix (ejection fraction, NYHA class,
number of co-morbid conditions, pacemaker/I CD etc) and variables potentially
associated with processes of care (primary care vs. cardiologist involvement in
care). Confounding is assessed by a change in the effect size of treatment caused
by inclusion of the potential confounder as a covariate. (HCFA Heart Failure
Demonstration Project, 2000)
Generalizability of Study Sample
To facilitate interpretation of study findings and estimate the generalizability of
findings, potentially eligible Medicare beneficiaries were screened for the study. Out of
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those screened and found eligible were included in the study. Eligible enrollees were
described in detail and compared to eligible non-enrollees according to all baseline data
provided by the refusers. However, the measures of statistical significance for these
comparisons were not reliable owing to the limited power.
Preliminary Analyses
Univariate
Because of random assignment, the two groups were not expected to differ on any
variable. If they differed on any variable related to an outcome or correlated highly with
an outcome, its confounding effect was adjusted using the variable as a covariate in
subsequent analyses. Univariate statistics (mean, median, SD, and SE) were computed
for all quantitative variables; for all dichotomous variables, counts and percentages, along
with SE, were computed.
Bivariate
Associations among all variables were examined for potential redundancy or
colinearity for subsequent regression analysis. The method of assessing the association
varied depending on the nature of the variables and the shape of their frequency
distributions. If there was an association, then the variables were adjusted in subsequent
analyses by stratification as covariates or by forced entry into regression equations.
The effects of the intervention were statistically tested using independent sample
1-tests, paired sample 1-tests, Mann-Whitney test, chi-square statistic, and Fisher's exact
tests, which, in tum, depended on the nature of the outcome variable and the shape of its
frequency distribution.
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Analysis of Endpoints
Integrated methods of distribution- and anchor-based methods were used. RTM is
a statistical phenomenon that occurs when repeated measurements are made on the same
subject or unit of observation (Barnett et aI., 2005). Values are observed with random
error; it is rare to observe data without random error, which makes RTM a common
phenomenon (Barnett et aI., 2005). RTM is a statistical phenomenon that may make
natural variation in repeated data appear to be real change (Barnett et aI., 2005). The
effect ofRTM in a sample becomes more noticeable when measurement error increases
due to repeated measurements in the sample (Barnett et aI., 2005).
Change over 6 months from the baseline was adjusted for RTM using the EN
method (Edwards et aI., 1978; Speer et aI., 1992). Regression to the normative group
mean was assessed by finding Spearman's or Pearson's correlation coefficients
(depending on the distribution) between the baseline and 6-month measurements,
between the baseline and change from the baseline to 6-month measure, and between the
absolute difference between the baseline and normative mean and the baseline to 6-month
change in measurement. If the RTM was significant, then the change from baseline to 6
months was adjusted for RTM using the EN method. If the RTM was not significant,
then the observed change from baseline to 6 months was taken into account without any
adjustment.
Adjustment for Regression to the Mean
The EN method classifies pre-post intervention changes as improved or
deteriorated based on 95% confidence intervals calculated using the EN index. If there

51

was RTM, an individual's true score or measurement would be closer to the mean of the
group than to the actual pretest score or measurement (Barnett et aI., 2005).
EN index = (f - X2)/SEM

(2)

where, t' is the true score or measurement

f = rt(X1-MG) + MG

(3)

where, rt is the reliability coefficient of the measure or instrument, and MG is the
mean of the normative group toward which the scores or measurements are
assumed to regress (Crosby et aI., 2004).
The EN CI is asymmetrical around the actual pretest score, whereas in the SEM
method, the CI centers on the pretest score.
To calculate the mean of the normative group, the sample was anchored to NYHA
Class II, III, and IV groups by stratification. Normative group means, SD, and SEM were
calculated for each group. Using the above formulae, each individual's true score, EN
index, and 95% confidence interval around the true score were calculated to establish
threshold values of cutoffs (true score ± 1.96* EN index). If the post-intervention score
or measurement after 6 months fell beyond the cutoffs, then the change from the baseline
was considered true change toward improvement or deterioration after adjusting for
RTM. To define whether this change was clinically meaningful or not, the change was
measured in terms ofSEM (i.e., true change after adjusting for RTM/SEM; see Figure 1).
Standard Error of Measurement
SEM was calculated using the formula SD* SQRT(l-rt), in which SD is the
standard deviation of the baseline measurement and SQRT is the square root (Anstassi &
Urbina, 1997; Redelmier et aI., 1997). If the magnitude of change from the baseline after
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-1 SEM change
Clinically
meaningful
Deterioration

Regression
to the Mean

r-"_1-.9-6-*-E-N-in-d-e-x---'1 /

+ 1 SEM change
Clinically meaningful
improvement

+ 1.96* ENindex

True bas line
score
~

No clinically meaningful change from baseline

Figure 1. Adjustment of regression to the mean and calculation of clinically meaningful
change.

correction to RTM was greater than or equal to 1 SEM, then that change was defined as
clinically meaningful (Wyrwich, Tierney, et aI., 1999). Based on the direction and
magnitude of change in terms of +/- SEM units, individuals were grouped into clinically
meaningful improvement, deterioration, or no change from baseline.
Assessment of the Effect of Technology-Driven Heart Failure Management System
Clinically meaningful change at the individual level was assessed by the SEM
method after adjusting the change over time to RTM. The statistical significance of
clinically meaningful change with respect to the standard care group and the standard
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care plus telemonitoring group was tested through a chi-square statistic; odds ratios were
calculated using a Mantle-Haenszel test. After defining groups with clinically
meaningful improvement, deterioration, or no change in functional capacity or QOL, the
group with no change was considered a reference group.
Multinomial regression analysis was performed to establish the best predictors of
clinically meaningful improvement and deterioration in functional capacity and QOL for
patients with HF. Both the control group and intervention group were controlled for all
possible potential confounders. Sensitivity and specificity of clinically meaningful
change in 6MWD and 6MW for predicting clinically meaningful change in MLHF score
were calculated.
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CHAPTER IV
RESULTS

Sample Description
A total of 284 participants who met eligibility criteria were randomized into either
a standard care group C!! = 142) or a technology-driven HF management group (g = 142).
Out of 142 participants in the standard care group, 36 were excluded from analysis due to
missing data (1 was a Pacific Islander, 4 lacked baseline characteristics documentation, 6
dropped out, 2 entered hospice, 2 suffered noncardiac deaths, and 21 were lost to followup). Out of 142 participants in the technology-driven HF management group, 47 were
excluded from analysis due to missing data (2 lacked baseline characteristics
documentation, 11 dropped out, 2 entered hospice, 2 suffered noncardiac deaths, and 30
were lost to follow-up).
Baseline characteristics, such as demographic variables, cardiovascular risk
factors, past medical history of cardiovascular diseases, and HF disease characteristics
(see Table 4), of the sample included in the study (g = 201) were compared with those of
the sample excluded from the analysis

C!L= 83) due to loss to follow-up or missing

information. The sample included in the analysis was not different from the group
excluded from the analysis. Distribution of baseline characteristics in the standard
medical care group and the technology-driven HF management group were tested. Tests
of normality showed baseline target variables (6MWD, 6MW, MLHF total score,
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emotional domain score, and physical domain score) were not normally distributed (see
Figures 2-6 and Table 3).

Technology-driven
management

~

~
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Missing baseline
information-2

[

J

"\
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'\

Pacific Islander-l

(

140
Dropped-II

Standard medical care

284 (total)

J

Missing baseline
information-4
137
--'00

"/

Dropped-6

....Hospice-2
Death
(noncardiac}-2

r
95

[

]

Lost to followup-30
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Lost to followup-2I

Figure 2. Sample attrition.
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Table 3
Tests of Normality for Baseline Target Variables
Shapiro-Wilk Test

Randomization
6MWD (baseline)

MLHF total score
(baseline)

Physical domain score
(baseline)

Emotional domain score
(baseline)

Static

Q.Q:
tailed)

df

Technology-driven
disease management

.941

95

.000

Standard medical care

.957

106

.002

Technology-driven
disease management

.965

95

.013

Standard medical care

.943

106

.000

Technology-driven
disease management

.950

95

.001

Standard medical care

.952

106

.001

Technology-driven
disease management

.909

95

.000

Standard medical care

.862

106

.000
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Estimation of Skewness and Kurtosis for Baseline Target Variable Distribution
The skewness and kurtosis of frequency distributions in the baseline 6MWD,
6MW, and QOL (MLHF) scores of the intervention vs. control groups were estimated
(see Table 4). Kurtosis is a measure of the peakedness or flatness of a distribution. A
kurtosis value near zero indicates a shape close to normal. A negative value indicates a
distribution that is more peaked than normal, and a positive kurtosis indicates a shape that
is flatter than normal. An extreme positive kurtosis indicates a distribution in which
more of the values are located in the tails rather than around the mean.
Skewness is the extent to which a distribution of values deviates from symmetry
around the mean. A value of zero means the distribution is symmetric. A positive
skewness indicates a greater number of smaller values, and a negative value indicates a
greater number of larger values.
In the Classic Principles of Statistics (1965), M.G. Bulmer suggests rule of
thumbs. If skewness is less than -lor greater than +1, the distribution is highly skewed.
If skewness is between -1 and -Yz or between +Yz and +1, the distribution is moderately
skewed. If skewness is between -Yz and +Yz, the distribution is approximately
symmetric. The reference standard is a normal distribution, which has a kurtosis of 3. In
token of this, often the excess kurtosis is presented: excess kurtosis = kurtosis-3. A
normal distribution has kurtosis exactly 3 (excess kurtosis exactly 0). Any distribution
with kurtosis::::; 3 (excess::::; 0) is called mesokurtic. A distribution with kurtosis < 3
(excess kurtosis < 0) is called platykurtic. Compared to a normal distribution, its central
peak is lower and broader, and its tails are shorter and thinner. A distribution with
kurtosis> 3 (~xcess kurtosis> 0) is called leptokurtic. Compared to a normal distribution,
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its central peak is higher and sharper, and its tails are longer and fatter (Bulmer, 1965; see
Table 4).

Table 4
Estimated Skewness and Kurtosis
Target variable

Skewness (SE)

Kurtosis (SE)

Technology-driven care

6-MWD

0.268 (0.250)

-1.239 (0.495)

6-MW

0.504 (0.250)

-0.897 (0.495)

MLHF total score

0.498 (0.250)

-0.382 (0.495)

-0.029 (0.250)

-1.217 (0.495)

0.847 (0.250)

-0.048 (0.495)

Physical dimension score
Emotional dimension score

Standard care

6-MWD

0.609 (0.236)

-0.233 (0.467)

6-MW

0.690 (0.236)

-0.152 (0.467)

MLHF total score

0.675 (0.236)

-0.346 (0.467)

Physical dimension score

0.321 (0.236)

-0.890 (0.467)

Emotional dimension score

1.075 (0.236)

0.432 (0.467)

Note. If the skewness or kurtosis statistic falls within the range of +/- 2 times the SE,
then it falls within the expected range of chance fluctuations (Tabachnick & Fidell, 1996).
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The 6MW, MLHF total score, and emotional dimension score were moderately
skewed in both the standard care and technology-driven care groups, whereas the 6MWD
values were skewed only in standard care group.
Comparison of Baseline Characteristics
The baseline characteristics of the intervention group receiving technology-driven
HF management and the control group receiving standard medical care were analyzed
using a chi-square test for equality of proportions or independent sample i-tests for
equality of means or a Mann-Whitney (U) test, when appropriate. Both groups were well
balanced with respect to their baseline characteristics, except for revascularization
procedures (see Table 5). There was statistically significant difference between the
standard care group and the technology-driven HF management group with respect to
history of revascularization procedures. About 50% ofthe participants in the technologydriven HF management group had undergone revascularization procedures, whereas in
the standard medical care group, only 36% had undergone revascularization procedures

(X2 = 4.409, df= 1, P = 0.036; see Table 5).
Description of Target Variables After 6 Months
Functional capacity (6MWD and 6MW) and QOL scores (MLHF scores) after 6
months for the group receiving technology-driven HF management were compared with
those of standard care group. The Mann-Whitney test statistic (U) and Z scores were
calculated. There was no significant difference between the two groups after 6 months
(see Table 6).
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Table 5
Baseline Characteristics

Characteristic

Standard
care
ill = 106)

Technologydriven HF
management
ill = 95)

75 ±8
27±6

74±7
28 +6

59
41

58
42

Demographic variables
Age in years (Mean)
BMI (Mean)
Gender
Male (%)
Female (%)
Race
Caucasians (%)
Others (%)
Marital status
Married (%)
Unmarried (%)
Cardiovascular risk factors
Smoking (%)
Hyperlipidemia (%)
Hypertension (%)
Diabetes (%)
Peripheral vascular diseases (%)
History of
Cerebrovascular accident/transient
ischemic attack (%)
Myocardial Infarction (%)
Revascularizations (%)
Valvular Abnormalities (%)
Disease characteristics
Duration ofHF in months (mean)
Left Ventricular Ejection Fraction
(Mean)
Type ofHF
Systolic (%)
Diastolic (%)
Systolic and diastolic (%)
Type of Cardiomyopathy
Ischemic (%)
Non-ischemic (%)

ILvalue
(2-tailed)

0.179
0.183
0.825

0.170
80
20

87
l3
0.155
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50
50

60
40

38
60
76
44
22

31
63
80
40
27

0.294
0.686
0.539
0.534
0.350

19

22

0.690

46
36
81

48
50
81

0.756
0.036 a
0.989

59 ±74
32 ±14

59 ±78
32 +14

0.990
0.817

58
l3
28

63
l3
24

0.564
1.000
0.526
0.458

49
51

54
46

Table 5 (continued)

Standard
care
ili = 106)

Characteristic
NYHAClass
II(%)
III & IV (%)
Disease management
Cardiologist on board
Pacemaker (%)
ICD (%)
Beta-blockers (%)
ACE-I/ARBs (%)
Target variables
6MWD in meters (mean)
6MW in kg/m (mean)
MLHF total score (mean)
Emotional dimension score (mean)
Physical dimension score (mean)

Technologydriven HF
management
ili = 95)

lLvalue
(2-tailed)
0.509

35
65

31
69

75
16
25
81
93

69
15
28
85
88

0.380
0.710
0.638
0.608
0.217

226 +144
213 ±118
1793 t±12187 17225210768
38 ±22
35 ±23
8 +7
7±7
17 ±11
18 ±11

0. 784b
0.877 b
0.219 b
0.127 b
0.216 b

aStatistically significant difference observed. bMann-Whitney (U) test.

Table 6
Target Variables After 6 Months for Standard Care vs. Technology-Driven Management

Target variable

6MWD(m)
6 MW (kg/m of work)
MLHF total score
Physical domain score
Emotional domain score

Standard
group
(mean)

Technologydriven
management
group
(mean)

189.14
15184.88
39.00
18.50
7.50

189.16
14342.54
38.00
17.90
7.60

65

Mann-Whitney test
U
Z
l2.G:
tailed)
5022
3673
4930
5006
4649

-0.320
-0.538
-0.255
-0.069
-0.945

0.975
0.590
0.799
0.945
0.345

The mean ofthe changes in functional capacity and QOL scores after 6 months
for the standard management group vs. the technology-driven HF management group
were not statistically significant (see Table 7).

Table 7
Mean Change in Functional Capacity and Quality of Life Over 6 Months

Target variable
mean change

6MWD(m)
6 MW (kg/m of work)
MLHF total score
Physical domain score
Emotional domain score

Standard
group
(mean)

Technology
driven
management
group
(mean)

33.48
2574.21
-3.40
-1.50
-0.84

20.44
2482.28
0.74
0.93
0.27

Mann-Whitney test
U
Z
P.Q:
tailed)
4731.5
3807.0
4814.0
4577.5
4981.0

-0.737
0.000
-0.537
-1.112
-0.132

0.461
1.000
0.591
0.266
0.895

Correlations Among Changes in Target Variables After 6 Months
After controlling for the treatment group assignment, the change in 6MWD after 6
months was correlated with changes in 6MW (r..= 0.892, Q..< 0.01), MLHF total score (r..=
-0.537, p < 0.01), physical domain score (r = -0.492, P. < 0.01), and emotional domain
score (r..= -0.468, Q..< 0.01) after 6 months. The change in 6MW after 6 months was also
correlated with changes in MLHF total score (r = -0.418, Q..< 0.01), physical domain
score (r = -0.364, Q..< 0.01), and emotional domain score (r = -0.350, Q..< 0.01) after 6
months. The change in physical domain score after 6 months was correlated with the
change in emotional domain score after 6 months (r = 0.762, P. < 0.01).
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Regression to the Mean
RTM is a statistical phenomenon that occurs when repeated measurements are
made on the same subject or unit of observation. R TM may make natural variation in
repeated data appear to be real change. It is rare to observe data without random error,
which makes RTM a common phenomenon (Barnett et aI., 2005). The effect ofRTM in
a sample becomes more noticeable when measurement error increases due to repeated
measurements in the sample.
The scatter plot of change in target variables over 6 months against baseline
measurements helped to identify RTM. The effect ofRTM should be adjusted with
appropriate statistical techniques. The scatter plots of change in target variable from
baseline to 6 months vs. the baseline target variable (e.g., 6MWD, 6MW, and QOL
[MLHF total score]) are depicted in Figures 8-10. These scatter plots provide visual
input on the effect of R TM on baseline target variables.
Assessment of Regression to Mean
Regression toward the normative mean was assessed by drawing partial
correlations between baseline and 6-month measurements, between baseline
measurements and change over 6 months, and between the absolute difference between
baseline and normative group mean and the absolute difference between baseline and 6month measurements of target variables (6MWD, 6MW, MLHF total score, MLHF
physical domain score, and MLHF emotional domain score).
Regression to Mean for Change in 6-Minute Walk Distance Over 6 Months
There were partial correlations between 6MWD at baseline and after 6 months (r
=

0.73, n...< 0.01) and between baseline 6MWD and change in 6MWD from baseline to 6
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months (r..= 0.27, 2-< 0.01). The absolute difference between the baseline 6MWD and
normative mean and the absolute difference between the baseline 6MWD and 6MWD
after 6 months (r = 0.15, 2-< 0.01) were statistically significant, indicating that RTM for
change in 6MWD after 6 months was statistically significant.
Regression to Mean for Change in 6-Minute Work after 6 Months
Pearson's correlations were made between 6MW at baseline and after 6 months (r

= 0.73, Q < 0.01) and between baseline 6MW and change in 6MW after 6 months (r =
0.30,2-< 0.01). The absolute difference between the baseline 6MW and normative mean,
and the absolute difference between the baseline 6 MW and 6 MW after 6 months (r =
0.28, P < 0.01) were statistically significant, indicating that RTM for change in 6MW
after 6 months was statistically significant.
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Regression to Mean for Change in MLHF Score after 6 Months
Partial correlations were made between the MLHF total score at baseline and after
6 months (r = 0.539, Q < 0.01) and the baseline MLHF total score and change in MLHF
total score after 6 months (r = 0.25, I2..< 0.01). The absolute difference between the
baseline MLHF total score and the normative mean and the absolute difference between
the baseline MLHF total score and the MLHF total score after 6 months (L= - 0.07, I2..=
0.30) were statistically significant, indicating that RTM for change in MLHF total score
from baseline to 6 months was statistically significant.
These findings suggested that the effect of R TM on target variable measurements'
at baseline and 6 months was statistically significant. Individuals with more severe
impairment in functional capacity or QOL at baseline exhibited greater change from
baseline to 6 months, and individuals with less impairment at baseline exhibited less
change from baseline to 6 months. Therefore, the change in 6MWD, 6MW, MLHF total
score, physical domain score, and emotional domain score from baseline to 6 months
should be adjusted to RTM.
Adjustment ofRTM for Change in Target Variables from Baseline to 6 Months
If the regression toward the group's normative was is significant, then the
differences between baseline and after 6 months values of target variables might have
understated or overstated the true change. Therefore, target variable change from
baseline to 6 months was adjusted to RTM using the EN method. According to the EN
method, the change in target variables from baseline to 6 months was classified as
improved, no change, or deteriorated based on confidence intervals calculated using
SEM. The change in measurements over time was adjusted for regression to the mean by
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establishing threshold values of +/-1.96* EN index (95% confidence interval) as cutoff
values to determine real or true change from baseline. Then clinically meaningful change
from baseline was calculated using SEM method (described later in this chapter; see
Table 8).

Table 8
Partial Correlations Between Target Variables at Baseline and Change From Baseline to
6 Months
Variables

Partial
correlations

6MWD
6MWD at baseline and after 6 months
Baseline 6MWD and change in 6MWD after 6 months
Absolute difference between baseline 6MWD and
normative mean and absolute difference between baseline
6MWD and 6MWD after 6 months
6MW
6MW at baseline and after 6 months
Baseline 6MW and change in 6MW after 6 months
Absolute difference between baseline 6MW and normative
mean and absolute difference between baseline 6MW and
6MW after 6 months
QOL (MLHF) total score
MLHF score at baseline and after 6 months
Baseline MLHF score and change in MLHF score after 6
months
Absolute difference between baseline MLHF score and
normative mean and absolute difference between baseline
MLHF score and MLHF score after 6 months
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Q (2-

tailed)

0.725
0.270
0.153

0.00
0.00
0.03

0.725
0.302
0.277

0.00
0.00
0.00

0.539
0.250

0.00
0.00

-0.072

0.30

For each participant, the EN index was calculated for each baseline measurement
by using Equation 2. The true score or measurement at baseline was calculated using
Equation 3. The normative group mean, SD, and SEM were calculated by anchoring the
study group to NYHA Class II, III, or IV. To determine the magnitude of true change
from the baseline, the cutoff values for change in target variables from baseline to 6
months (95% confidence interval) were determined by calculating +1-1.96*(EN index).
The cutoff values (95% confidence interval) to determine true change from the baseline
values for 6MWD, MLHF total score, physical domain score, and emotional domain
score were determined by calculating +1-1.96*(EN index) for each patient.
Therefore, if the change in 6MWD, MLHF total score, physical domain score, and
emotional domain score fell within the range of cutoff values +1-1.96*(EN index), then
the change was not real and was due to the effect ofRTM. If the magnitude of change
from the baseline to 6 months fell beyond the cutoff values, then the change was real
after adjusting to RTM.
Determination of Clinically Meaningful Change in Target Variables From Baseline to 6
Months
If the magnitude of change from the baseline cutoff values was greater than or
equal to I SEM, then it was defined as clinically meaningful (Wyrwich et ai., 1996).
Based on the direction and magnitude of change in terms of +I-SEM units, individuals
were grouped according to clinically meaningful improvement, deterioration, or no
change from the baseline. SEM was calculated using the formula SD* SQRT(l- rD, in
which SD is standard deviation of the baseline measurement and SQRT is the square root
(Anstasi et ai., 1997; Redelmier et ai., 1997). After adjusting the change from baseline to
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RIM, the cutoff values for true change in the target variables from baseline to 6 months
(6MWD, 6MW, MLHF total score, MLHF physical domain score, and MLHF emotional
domain score) were determined in terms of +/-1 unit of SEM.
If the magnitude of true change in the target variables fell beyond +/-1 unit of
SEM, then it was clinically meaningful. If the magnitude of true change in target
variables fell within the range of cutoff values (+/-1 SEM unit), then it was true change
but not clinically meaningful. Change in 6MWD by 42 m (or 39 m-42 m), in 6MW by
3,668 kg/m of work (or 3,063-3,820), in MLHF total score by 6.0 points (or 5.0-7.0), in
physical domain by 4.0 points (or 3.0-4.0), and emotional domain by 2.0 points (or 2.03.0) were considered clinically meaningful change in patients with chronic CHF (see
Tables 9 and 10).

Table 9
Standard Error of Measurement for Target Variables
Reliability
coefficient of
measurement
Target variable
6MWD(m)
6MW (kg/m of work)
MLHF total score
Physical domain score
Emotional domain score

Mean
220.43
17326.28
36.70
17.55
7.09

SD
133.00
14857.16
23.22
11.12
6.64

73

(rt)

0.90
0.90
0.93
0.89
0.88

SEM
42.06
3667.61
6.14
3.69
2.30

Table 10
Standard Error of Measurement for Target Variable After Anchoring by NYHA Class

Target variable

Mean

NYHA Class II
6MWD(m)
307.74
6MW (kg/m of work)
24968.17
26.74
MLHF total score
Physical domain score
12.00
Emotional domain score
5.24

SD

Reliability
coefficient
of
measurement
(rt)

SEM

125.21
11236.05
19.91
9.54
5.59

0.90
0.90
0.93
0.89
0.88

39.59
3553.15
5.27
3.16
1.94

NYHA Class III
6MWD(m)
6MW (kg/m of work)
MLHF total score
Physical domain score
Emotional domain score

183.23
14363.49
41.34
20.18
7.8

111.41
9688.37
22.79
10.89
6.76

0.90
0.90
0.93
0.89
0.88

35.23
3063.73
6.03
3.61
2.34

NYHA Class IV
6MWD(m)
6MW (kg/m of work)
MLHF total score
Physical domain score
Emotional domain score

144.25
11177.32
42.95
20.79
9.16

132.90
12090.92
26.38
10.97
8.09

0.90
0.90
0.93
0.89
0.88

42.03
3823.48
6.98
3.64
2.80

Clinically Meaningful Change in 6MWD for Standard Care Vs. Technology-Driven
Disease Management
Based on the direction and magnitude of change in terms of +/-1 SEM units for
target variables, individuals were divided into three groups: (a) clinically meaningful
improvement, (b) no change, and (c) clinically meaningful deterioration from the
baseline. Participants who died from cardiovascular disease were included in the
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deterioration group. In comparing the standard care vs. technology-driven HF
management groups, there was no statistically significant difference with respect to
clinically meaningful change in 6MWD after 6 months (see Table 11).

Table 11
Clinically Meaningful Change in 6MWD in Standard Care vs. Technology-Driven
Disease Management

Randomization

Total

Technology
drivendisease
management
Standard
medical care

Clinically meaningful change in
6MWD
DeterioImproved
No
rated
change
21
41
33
22.1%
43.2%
34.7%

Count
% within
randomization
Count
% within
randomization
Count
% within
randomization

Total

95
100.0%

21
19.8%

45
42.5%

40
37.7%

106
100.0%

42
20.9%

86
42.8%

73
36.3%

201
100.0%

Note. X2 = 0.256, df = 2, 12 (2-tailed) = 0.880.

Addition of technology-driven teiemonitoring to standard therapy didn't provide
any additional clinically meaningful impact on functional capacity measured in terms of
6-MWD. After stratification of both groups into NYHA Class II and Class III/IV, the
effect oftelemonitoring was still not significant (see Table 12).
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Table 12
Clinically Meaningful Change in 6MWD for Standard Care vs. Technology-Driven
Disease Management After Stratification
Clinically meaningful
change in 6MWD
ImDeteriNo
orated
change ~roved
15
23
28
22.7%
42.4%
34.8%

NY
HA
clas
s

III & Randomi-

Total

66
Count
100.0%
IV
zation
% within
randomization
23
Count
14
32
69
% within
20.3%
46.4%
33.3% 100.0%
randomization
46
29
135
Total
Count
60
% within
21.5%
44.4%
34.1% 100.0%
randomization
RandomiTechnology Count
10
29
6
II
13
drivenzation
% within
20.7%
44.8%
34.5% 100.0%
disease
randomimanagement zation
Standard
Count
7
13
17
37
medical care % within
45.9% 100.0%
18.9%
35.1%
randomization
Total
Count
26
66
27
13
% within
40.9% 100.0%
19.7%
39.4%
randomiz
ation
Note. For NYHA Class II, X2 = 0.235, df= 2, and IL(2-tailed) = 0.889. For NYHA
Classes III and IV, X2 = 0.936, df= 2, and Q (2-tailed) = 0.626.
Technology
drivendisease
management
Standard
medical care
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Clinically Meaningful Change in 6MW from Baseline to 6 Months for Standard Care V s.
Technology-Driven Disease Management
In comparing standard care and technology-driven disease management groups,
there was no statistically significant difference with respect to clinically meaningful
change in 6MW after 6 months (see Table 13). Addition of technology-driven
telemonitoring to standard medical therapy didn't provide any additional clinically
meaningful benefits in tenns of functional capacity as measured by 6MW. After
stratification of both groups into NYHA Class II and Class III/IV, the effect of
telemonitoring was still not significant (see Table 14).

Table 13
Clinically Meaningful Change in 6MW for Standard Care vs. Technology-Driven
Disease Management

Randomization

Total

Technology
drivendisease
management
Standard
medical care

Count
% within
randomization
Count
% within
randomization
Count
% within
randomization

Note. X 2 = 0.131, df= 2, Q (2-tailed) = 0.937.
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Clinically meaningful change
in6MW
ImDeteriNo
orated
change
Qroved
16
38
26
47.5%
32.5%
20.0%

Total

80
100.0%

18
19.1%

43
45.7%

33
35.1%

94
100.0%

34
19.5%

81
46.6%

59
33.9%

174
100.0%

Table 14
Clinically Meaningful Change in 6MW for Standard Care vs. Technology-Driven Disease
Management After Stratification
NYHA
class

III
&

IV

Randomization Technology
drivendisease
management
Standard
medical care
Total

Count
% within
randomization
Count
% within
randomization
Count
% within
randomization
Count
% within
randomization

Clinically meaningful
Total
change in 6 MW
Deterio
No
Im-rated
change .Qroved
11
25
20
56
19.6% 44.6% 35.7% 100.0%

13
20.3%

31
48.4%

64
20
31.3% 100.0%

24
20.0%

56
46.7%

40
120
33.3% 100.0%

13
54.2%

6
24
25.0% 100.0%

12
40.0%

13
30
43.3% 100.0%

25
46.3%

19
54
35.2% 100.0%

Randomization Technology
5
20.8%
drivendisease
management
Count
Standard
5
16.7%
medical care % within
randomization
Total
Count
10
% within
18.5%
randomization
Note. For NYHA Class II, X2 = 1.463, df = 2, and IL(2-tailed) =
III and IV, X 2 = 1.186, df= 2, and IL(2-tailed) = 0.359.
II
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0.481. For NYHA Class

Clinically Meaningful Change in QOL From Baseline to 6 Months for Standard Care Vs.
Technology-Driven Disease Management
In comparing standard care and technology-driven disease management, there was
no statistically significant difference with respect to clinically meaningful change in
MLHF total score after 6 months (see Table 15). Addition of technology-driven
telemonitoring to standard medical therapy didn't provide any additional clinically
meaningful benefit for QOL measured in terms of MLHF score. After stratification of
both groups into NYHA Class II and Class III/IV, the effect of telemonitoring was still
not significant (see Table 16).

Table 15
Clinically Meaningful Change in MLHF Total Score for Standard Care vs. TechnologyDriven Disease Management

Randomization Technology
drivendisease
management
Standard
medical care
Total

Count
% within
randomization
Count
% within
randomization
Count
% within
randomization

Note. X2 = 3.877, df= 2, 2 (2-tailed) = 0.144.
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Clinically meaningful change
in MLHF total score
No
DeteriImproved
orated
change
38
30
27
28.4%
40.0% 31.6%

30
28.3%

46
43.4%

30
28.3%

Total

95
100.0
%
106
100.0
%

68
33.8%

76
37.8%

57
28.4%

201
100.0
%

Table 16
Clinically Meaningful Change in MLHF Total Score for Standard Care vs. TechnologyDriven Disease Management After Stratification
NYHA
Class

III
&
IV

Randomization

Technology
drivendisease
management
Standard
medical care

Count
% within
randomization

Clinically meaningful change Total
in MLHF total score
DeteriImNo
orated
change 12roved
21
66
21
24
36.4% 31.8%
31.8% 100.0%

19
69
Count
20
30
% within
29.0% 43.5%
27.5% 100.0
%
randomization
51
40
135
Total
Count
44
% within
32.6% 37.8%
29.6% 100.0
%
randomization
14
9
6
29
II
Randomization Technology Count
48.3% 31.0%
driven% within
20.7% 100.0
%
disease
randomization
management
16
11
Standard
Count
10
37
27.0% 43.2%
medical care % within
29.7% 100.0
%
randomization
17
66
Count
24
25
Total
% within
36.4% 37.9%
25.8% 100.0
%
randomization
Note. For NYHA Class II, X2 = 3.174, df= 2, and p (2-tailed) = 0.205. For NYHA
Class III and IV, X2 = 1.986, df = 2, and n...(2-tailed) = 0.370.
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Clinically Meaningful Change in Physical Domain Score from Baseline to 6 Months for
Standard Care Vs. Technology-Driven Disease Management
In comparing standard care vs. technology-driven disease management, there was
no statistically significant difference with respect to clinically meaningful change in
MLHF physical dimension score after 6 months (see Table 17). Addition of technologydriven telemonitoring to standard medical therapy didn't provide any additional clinically
meaningful benefit for the physical domain of MLHF score. After stratification of both
groups into NYHA Class II and Class III/IV, the effect of telemonitoring was still not
significant (see Table 18).

Table 17
Clinically Meaningful Change in MLHF Physical Domain Score for Standard Care vs.
Technology-Driven Disease Management

Randomization

Total

Technology
drivendisease
management
Standard
medical care

Count
% within
randomization
Count
% within
randomization
Count
% within
randomization

Note. X2 = 0.309, df= 2, 2 (2-tailed) = 0.857.
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Clinically meaningful change
in 12hysical domain score
Improved
DeteriNo
orated
change
19
61
15
15.8%
20.0% 64.2%

Total

95
100.0%

18
17.0%

71
67.0%

17
106
16.0% 100.0%

37
18.4%

l32
65.7%

32
15.9%

201
100.0%

Table 18
Clinically Meaningful Change in MLHF Physical Domain Score for Standard Care vs.
Technology-Driven Disease Management After Stratification
Clinically meaningful
Total
change in physical domain
score
ImDeterioNo
rated
change J2roved
15
41
10
66
22.7% 62.1% 15.2% 100.0%

NYHA
Class

III
&
IV

Randomization

Technology Count
% within
drivendisease
randomization
management
Standard
Count
15
12
69
42
medical care % within
21.7% 60.9% 17.4% 100.0%
randomization
30
83
22
135
Total
Count
22.2% 61.5% 16.3% 100.0%
% within
randomization
4
20
RandomiTechnology Count
5
29
II
driven% within
13.8% 69.0% 17.2% 100.0%
zation
disease
randomization
management
Count
3
29
5
37
Standard
8.1% 78.4% 13.5% 100.0%
medical care % within
randomization
66
49
10
Count
7
Total
% within
10.6% 74.2% 15.2% 100.0%
randomization
Note. For NYHA Class II, X2 = 0.839, df= 2, and Q...(2-tailed) = 0.658. For NYHA Class
III and IV, X2 = 0.127, df= 2, and I!..(2-tailed) = 0.938.
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Clinically Meaningful Change in MLHF Emotional Domain Score From Baseline to 6
Months for Standard Care Vs. Technology-Driven Disease Management
In comparing standard care and technology-driven disease management, there was
no statistically significant difference with respect to clinically meaningful change in
MLHF emotional dimension score after 6 months (see Table 19). Addition of technology
driven telemonitoring to standard medical therapy didn't provide any additional clinically
meaningful benefit for the emotional domain of MLHF score. After stratification of both
groups into NYHA Class II and Class IIIIIV, the effect of telemonitoring was still not
significant (see Table 20).

Table 19
Clinically Meaningful Change in MLHF Emotional Domain Score for Standard Care vs.
Technology-Driven Disease Management

Randomization Technology
drivendisease
management
Standard
medical care
Total

Count
% within
randomization
Count
% within
randomization
Count
% within
randomization

Note. X2 = 0.762, df = 2, 12..(2-tailed) = 0.683
Table 20
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Clinically meaningful
change in emotional domain
score
No
ImDeteriorated change
Qroved
5
87
3
3.2%
5.3% 91.6%

Total

95
100.0%

6
5.7%

94
88.7%

6
5.7%

106
100.0%

11

181
90.0%

9
4.5%

201
100.0%

5.5%

Clinically Meaningful Change in MLHF Emotional Domain Score for Standard Care
Group vs. Technology-Driven Disease Management After Stratification
Total
Clinically meaningful
change in emotional
domain score
ImNo
Deteriorated change Eroved
66
4
59
3
6.1%
89.4%
4.5% 100.0%

NYHA
Class

Technology Count
driven% within
disease
randomization
management
69
Count
6
57
6
Standard
medical care % within
8.7%
82.6%
8.7% 100.0%
randomization
10
116
9
135
Total
Count
85.9%
6.7%100.0%
% within
7.4%
randomization
29
1
28
RandomiTechnology Count
II
driven100.0%
zation
% within
3.4% 96.6%
disease
randomization
management
37
Count
0
37
Standard
.0% 100.0%
medical care % within
100.0%
randomization
1
65
66
Count
Total
100.0%
% within
1.5% 98.5%
randomization
Note. For NYHA Class II, X2 = 1.295, df= 2" and JL(2-tailed) = 0.439. For NYHA
Class III and IV, X2 = 1.368, df = 2, and JL(2-tailed) = 0.504.

III
&
IV

Randomization

84

Clinically Meaningful Change in 6MWD to Predict Clinically Meaningful Similar
Directional Change in MLHF Score
1. Clinically meaningful improvement in 6MWD to predict clinically meaningful
improvement in MLHF score: sensitivity = 56.1 %, specificity = 71.5%, positive
predictive value = 43.8%, negative predictive value = 80.5%, agreement = 67%.
2. Clinically meaningful deterioration in 6MWD to predict clinically meaningful
deterioration in MLHF score: sensitivity = 35.3 %, specificity = 86.5%, positive
predictive value = 57.1 %, negative predictive value = 72.3%, agreement = 69%.
3. No clinically meaningful change in 6MWD to predict no clinically meaningful
change in MLHF score: sensitivity = 44.7 %, specificity = 58.4%, positive
predictive value = 39.5%, negative predictive value = 63.4%, agreement = 53.2%
(see Table 21).
Clinically Meaningful Change in 6MWD to Predict Clinically Meaningful Similar
Directional Change in MLHF Physical Domain Score
1. Clinically meaningful improvement in 6MWD to predict clinically meaningful
improvement in MLHF physical domain score: sensitivity = 68.8%, specificity =
69.8%, positive predictive value = 30.1 %, negative predictive value = 92.2%,
agreement = 69.7%.
2. Clinically meaningful deterioration in 6MWD to predict clinically meaningful
deterioration in MLHF physical domain score: sensitivity = 35.1 %, specificity =
82.3%, positive predictive value = 31.0%, negative predictive value = 85.0%,
agreement = 73.6%.

85

Table 21
Clinical Meaningful Change in 6MWD vs. Clinically Meaningful Change in MLHF Total
Score
Clinically meaningful change in MLHF
total score
Deteriorated
No
Improved

Total

chan~e

Clinically meaningful
change in 6MWD

Deteriorated

24
57.1%
30
34.9%
14
19.2%
68
33.8%

No change
Improved
Total

15
35.7%
34
39.5%
27
37.0%
76
37.8%

3
42
7.1% 100.0%
22
86
25.6% 100.0%
32
73
43.8% 100.0%
57
201
28.4% 100.0%

Note. X 2 = 24, df= 4, 12 < 0.001; Spearman correlation = 0.345, 12 < 0.001; Kappa =
0.169,12< 0.001.

3. No clinically meaningful change in 6MWD to predict no clinically meaningful
change in MLHF physical domain score: sensitivity = 46.2 %, specificity =
63.8%, positive predictive value = 71.0%, negative predictive value = 38.3%,
agreement = 52.2% (see Table 22).
Clinically Meaningful Change in 6MWD to Predict Clinically Meaningful Similar
Directional Change in MLHF Emotional Domain Score
1. Clinically meaningful improvement in 6MWD to predict clinically meaningful
improvement in MLHF emotional domain score: sensitivity = 100%, specificity =
66.7%, positive predictive value = 12.3%, negative predictive value = 100%,
agreement = 68.1 %.
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Table 22
Clinically Meaningful Change in 6MWD vs. Clinically Meaningful Change in Physical
Dimension Score

Deteriorated
Clinically
meaningful change in
6MWD
No change
Improved
Total

Clinically meaningful change in physical
domain score
Deteriorated
No
Improved
change
2
13
27
31.0%
64.3%
4.8%
17
61
8
19.8%
70.9%
9.3%
7
44
22
9.6%
60.3%
30.1%
132
32
37
18.4%
65.7%
15.9%

Total

42
100.0%
86
100.0%
73
100.0%
201
100.0%

Note. X2 = 22.37, df = 4, IL< 0.001; Spearman correlation = 0.31, Q < 0.001; Kappa =
0.161, Q < 0.001.

2. Clinically meaningful deterioration in 6MWD to predict clinically meaningful
deterioration in MLHF emotional domain score: sensitivity = 63.6%, specificity =
81.6%, positive predictive value = 16.7%, negative predictive value = 97.5%,
agreement = 80.6%.
3. No clinically meaningful change in 6MWD to predict no clinically meaningful
change in MLHF emotional domain score: sensitivity = 45.3 %, specificity =
80%, positive predictive value = 95%, negative predictive value = 14%,
agreement = 49% (see Table 23).
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Table 23
Clinically Meaningful Change in 6MWD vs. Clinically Meaningful Change in Emotional
Dimension Score

Clinically
meaningful change
in6MWD

Deteriorated
No change
Improved

Total

Clinically meaningful change in
emotional domain score
Deteriorated
No
Improved
change
0
7
35
16.7%
83.3%
.0%
4
82
0
.0%
4.7%
95.3%
0
64
9
.0%
87.7%
12.3%
181
9
11
5.5%
90.0%
4.5%

Total

42
100.0%
86
100.0%
73
100.0%
201
100.0%

Note. X2 = 30.02, df= 4,.Q..< 0.001; Spearman correlation = 0.35, II < 0.001; Kappa =
0.127, II < 0.001.

Clinically Meaningful Change in 6MW to Predict Clinically Meaningful Similar
Directional Change in MLHF Score
1. Clinically meaningful improvement in 6MW to predict clinically meaningful
improvement in MLHF score: sensitivity = 56%, specificity = 75%, positive
predictive value = 47.5%, negative predictive value = 81 %, agreement = 69.5%.
2. Clinically meaningful deterioration in 6MW to predict clinically meaningful
deterioration in MLHF score: sensitivity = 32.8 %, specificity = 87%, positive
predictive value = 56%, negative predictive value = 72%, agreement = 69%.
3. No clinically meaningful change in 6MW to predict no clinically meaningful
change in MLHF score: sensitivity = 53 %, specificity \= 57.4%, positive
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predictive value = 43.2%, negative predictive value = 66.7%, agreement = 55.7%
(see Table 24).

Table 24
Clinically Meaningful Change in 6MW vs. Clinically Meaningful Change in MLHF
Score

Clinically meaningful
change in 6MW

Deteriorated
No change
Improved

Total

Clinically meaningful change in MLHF
total score
Deteriorated
Improved
No
change
19
13
2
38.2%
55.9%
5.9%
26
20
35
32.1%
43.2%
24.7%
13
18
28
22.0%
30.5%
47.5%
58
66
50
33.3%
37.9%
28.7%

Total

34
100.0%
81
100.0%
59
100.0%
174
100.0%

2

Note. X = 22.8, df= 4, n...< 0.001; Spearman correlation = 0.33, Q < 0.001; Kappa =

0.200, Q < 0.001.

Clinically Meaningful Change in 6MW to Predict Clinically Meaningful Similar
Directional Change in MLHF Physical Domain Score
1. Clinically meaningful improvement in 6MW to predict clinically meaningful
improvement in MLHF physical domain score: sensitivity = 69.3%, specificity =
72.3%, positive predictive value = 30.5%, negative predictive value = 93%,
agreement = 72%.
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2. Clinically meaningful deterioration in 6MW to predict clinically meaningful
deterioration in MLHF physical domain score: sensitivity = 34.4 %, specificity =
83.4%, positive predictive value = 32.5%, negative predictive value = 85.0%,
agreement = 74.7%.
3. No clinically meaningful change in 6MW to predict no clinically meaningful
change in MLHF physical domain score: sensitivity = 51 %, specificity = 62%,
positive predictive value = 73%, negative predictive value = 38.7%, agreement =
54.6% (see Table 25).

Table 25
Clinically Meaningful Change in 6MW vs. Clinically Meaningful Change in Physical
Dimension Score

Clinically
meaningful change
in6MW

Deteriorated
No change
Improved

Total

Clinically meaningful change in physical
domain score
Deteriorated
No
Improved
change
1
11
22
32.4%
64.7%
2.9%
15
59
7
18.5%
72.8%
8.6%
6
18
35
59.3%
10.2%
30.5%
32
116
26
18.4%
66.7%
14.9%

Total

34
100.0%
81
100.0%
59
100.0%
174
100.0%

Note. X 2 = 21.7, df= 4,.Q...< 0.001; Spearman correlation = 0.32, Q < 0.001; Kappa =
0.l8, Q < 0.001.
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Clinically Meaningful Change in 6MW to Predict Clinically Meaningful Similar
Directional Change in MLHF Emotional Domain Score
1. Clinically meaningful improvement in 6MW to predict clinically meaningful
improvement in MLHF emotional domain score: sensitivity = 89%,
specificity = 69%, positive predictive value = 13.6%, negative predictive
value = 99%, agreement = 70%.
2. Clinically meaningful deterioration in 6MW to predict clinically meaningful
deterioration in MLHF emotional domain score: sensitivity = 45.4%,
specificity = 82%, positive predictive value
value

= 14.7%, negative predictive

= 95.7%, agreement = 80%.

3. No clinically meaningful change in 6MW to predict no clinically meaningful
change in MLHF emotional domain score: sensitivity = 48.7 %, specificity =
70%, positive predictive value = 92.6%, negative predictive value = 15%,
agreement = 51 % (see Table 26).
Agreement Between NYHA Class and 6MWD in Assessing the Severity of Heart Failure
Of participants, 4% had mildly impaired functional capacity, but 33% were
classified under NYHA Class II. Only 25% had moderately impaired functional capacity,
but 58% were classified under NYHA Class III. For 71 % of the participants functional
capacity was severely impaired, but only 10% were classified under NYHA Class IV.
Objectively measured functional capacity in terms of 6MWD was weakly correlated with
physician-assessed severity (NYHA class) ofHF condition (spearman correlation (S)

=

0.365,12.< 0.05). The agreement between these two methods was very poor (18%) and
not statistically significant (Kappa = -0.38, Q...= 0.173; see Table 27).
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Table 26
Clinically Meaningful Change in 6MW V s. Clinically Meaningful Change in Emotional
Dimension Score

Clinically
meaningful change
in6MW

Deteriorated
No change
Improved

Total

Clinically meaningful change in
Total
emotional domain score
Deteriorated
No
Improved
change
5
29
0
34
14.7%
85.3%
.0% 100.0%
5
75
1
81
92.6%
1.2% 100.0%
6.2%
50
8
59
1
13.6%
1.7%
84.7%
100.0%
11
154
174
9
6.3%
88.5%
5.2% 100.0%

Note. X2 = 18.28, df = 4, 1L< 0.001; Spearman correlation = 0.293, 12 < 0.001; Kappa =
0.114, 12 < 0.001.

Table 27
Agreement Between NYHA Class and Functional Ca12acity

NYHA class at
baseline

II

III

IV

Total

Count
%of
total
Count
%of
total
Count
%of
total
Count

6MWD at baseline
>450m
301-450 m <300m
29
7
30

Total
66

3.5%

14.4%

14.9%

32.8%

1
.5%

17
8.5%

98
48.8%

116
57.7%

0
.0%

4
2.0%

15
7.5%

19
9.5%

8

50

143

201

4.0%
%of
24.9%
71.1%
100.0
total
%
Note. X2 = 34.68, df= 1,12 < 0.05; Kap12a = -0.038, 1L= 0.173; agreement = 18%.
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There is lack of agreement between objective assessment ofNYHA functional
class and objective measuring of functional capacity because either patients or physicians
are under- or over-estimating functional capacity compared to objectively measured
values. The method of assessing NYHA class is arbitrary, and intraoperator variability is
66% (Claire et aI., 2007). When assessing NYHA class, many clinicians simply ask
patients with HF exertion symptoms how far they can walk or exert themselves before
symptom onset.
On the other hand, 6MWD (measured in meters) may not be a sole indicator of
severity of CHF condition, especially when comparing individuals with different ages,
genders, BMls, and comorbid conditions. The NYHA system and 6MWD are regularly
used as outcome measures in clinical trials and are even included in HF management
guidelines. Thus, the lack of agreement and consistency between these two classification
methods suggests the need for development of novel classification methods by designing
norm-referenced equations comprising age, gender, BMI, comorbid conditions,
symptoms, and signs of HF.
Predictors of Clinically Meaningful Change in 6MWD
Clinically relevant independent variables were selected from baseline
characteristics to predict 6MWD. These variables were age, BMI, ejection fraction,
history of diabetes, history of coronary artery disease, history of coronary
revascularizations, history of peripheral vascular disease, diastolic HF, beta-blocker
usage, ACE/ARBs usage, history of ICD implantation, and telemonitoring usage.
Multinomial logistic regression analysis was performed by entering variables through an
entry method into the main effects model. The category of participants with no
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meaningful change in 6MWD was selected as the reference category. Multinomial
regression analysis was performed on 181 participants (20 were missing data; see Table
28).
The probability ofthe model's chi-square (X2 = 48.699, df= 24, II = 0.002) was
statistically significant (ll < 0.05). The null hypothesis that there was no difference
between the model without independent variables and the model with independent
variables was rejected. The existence of a relationship between the independent variables
and the dependent variable was supported (see Table 29).
The benchmark to characterize this multinomial logistic regression model as
useful was a 25% improvement over the rate of accuracy achievable by chance alone.
The proportional by-chance accuracy rate was computed by calculating the proportion of
cases for each group (improved, deteriorated, and no change) based on the number of
cases in each group in the marginal percentages of the case processing summary, as
previously described, and then squaring and summing the proportion of cases in each
group: 0.3772 + 0.2102 + 0.1712. The proportional by-chance accuracy criterion was
44.5% % (1.25 x 35.6% = 44.5%). The classification accuracy rate ofthis model should
be greater than the proportional by chance accuracy criterion of 44.5%.
The chi-square statistic was the difference in -2 log likelihoods between the final
model and a reduced model. The reduced model was formed by omitting an effect from
the final model. The null hypothesis was that all parameters of that effect are zero. The
reduced model was equivalent to the final model because omitting the effect did not
increase the degrees of freedom. The likelihood ratio tests for BMI, ejection fraction,
history of diabetes, beta-blocker usage were statistically significant (Q < 0.05) and
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Table 28
Case Processing Summary for Predictors of Clinically Meaningful Change in 6MWD

N
Clinically meaningful
change in 6MWD

Improved

Marginal ~ercentage
37.6%
68

Deteriorated

38

21.0%

No change

75

41.4%

Diabetes mellitus-II
(DM-II)

Yes

75

41.4%

No

106

58.6%

History of CAD

Yes

139

76.8%

No

42

23.2%

Yes

77

42.5%

No

104

57.5%

45

24.9%

136

75.1%

Yes

25

13.8%

No

156

86.2%

Yes

150

82.9%

No

31

17.1%

Yes

165

91.2%

No

16

8.8%

Yes

53

29.3%

No

128

70.7%

Technology-driven disease
management

82

45.3%

Standard medical care

99

54.7%

181

100.0%

Revascularization
procedures

Peripheral vascular disease Yes
(PVD)
No
Diastolic HF
Beta-blocker usage
ACE-I1ARBs usage
ICD implantation
Randomization

Valid

20

Missing

201
181 a

Total

Sub,Qo,Qulation
aThe dependent variable had only one value observed in 181 (100.0%) subpopulations.
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Table 29
Model Fitting Information for Predictors of Clinically Meaningful Change in 6MWD
Model

Intercept only
Final

Model-fitting
criteria
-2 log
likelihood
383.923
335.224

Likelihood ratio tests
Chi-square

df

48.699

24

.002

suggestive of significant prediction of clinically meaningful change in 6MWD (see Table
30).
BMI, LVEF, diabetes, and beta-blocker usage were significant predictors for
differentiating clinically meaningful improvement in 6MWD vs. no clinically meaningful
change in 6MWD, whereas beta-blocker usage was the only variable significant enough
to differentiate clinically meaningful deterioration in 6MWD vs. no clinically meaningful
change in 6MWD (see Table 31).
The classification accuracy for clinically meaningful improvement in 6MWD was
65% and for no meaningful change in 6MWD, was 69%. The classification accuracy for
clinically meaningful deterioration in 6MWD was 16%. The overall prediction accuracy
ofthis model was 56.4%, which was greater than that of classification accuracy by
chance alone (i.e., 44.5%; see Table 32). Therefore, this prediction model was valid to
predict clinically meaningful change in 6MWD.
Predictors of Clinically Meaningful Change in 6MW
Clinically relevant independent variables were selected from baseline
characteristics to predict 6MW. The variables included age, BMI, ejection fraction,
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Table 30
Likelihood Ratio Tests for Predictors of Clinically Meaningful Change in 6MWD

Effect
Intercept
Age
Body-mass index
(BMI)
Left ventricular
ejection fraction
(LVEF)
Diabetes mellitus-II
(DM-II)
History of CAD
History of
Revascularizations
History of
peripheral vascular
disease (PVD)
Diastolic HF
Beta-blocker usage
ACE-I1ARBs usage
History ofICD
implantation
Telemonitoring

Model-fitting
criteria
-2 log
likelihood
3.352E2
337.427
346.897

Chi-sguare
.000
2.203
11.673

348.680

Likelihood ratio tests
df

Sig.
0
2
2

.332
.003

13.456

2

.001

342.222

6.998

2

.030

336.610
337.002

1.386
1.778

2
2

.500
.411

336.134

.910

2

.635

339.441
341.963
336.529
340.091

4.217
6.739
1.306
4.867

2
2
2
2

.121
.034
.521
.088

336.757

1.533

2

.465
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Table 31
Parameter Estimates for Predictors of Clinically Meaningful Change in 6MWD

Clinically meaningful
change in 6MWD a
Improved Intercept
Age
BMI
LVEF
DM-II
CAD
Revasculari zation
PVD
Diastolic HF
Beta-blocker
usage
ACE-I1ARBs
usage
ICD implantation
Te1emonitoring
Deterior- Intercept
Age
ated
BMI
LVEF
DM-II
CAD
Revasculari zation
PVD
Diastolic HF
Beta-blocker
usage
ACE-I1ARBs
usage
ICD implantation
Telemonitoring

B
10.246
-.045
-.134
-.071
.824
-.578
-.437

SE
Wald
3.295 9.671
.031 2.136
.042 9.919
.020 12.307
.411 4.026
.505 1.307
.429 1.039

.346
1.650
-1.241

.429
.845
.573

.653
3.809
4.695

-.269

.652

.170

.774

.436

-.176
2.900
-.016
-.026
-.033
-.341
-.144
-.567

95% confidence
b
interval for eXE
Lower Upper
Expb bound bound

Sig.
.002
.144 .956 .901
.002 .875 .805
.000 .932 .896
.045 2.281 1.019
.253 .561 .208
.308 .646 .278

1.015
.951
.969
5.103
1.511
1.497

.419 1.414
.051 5.205
.030 .289

.610
.993
.094

3.276
27.280
.888

.764

.213

2.740

3.148

.076 2.169

.922

5.100

.401
3.435
.033
.041
.021
.475
.543
.481

.193
.713
.225
.396
2.387
.515
.071
1.387

.660
.398
.635
.529
.122
.473
.790
.239

.839

.382

1.839

.985
.975
.967
.711
.866
.567

.923
.900
.927
.280
.299
.221

1.050
1.056
1.009
1.805
2.508
1.457

-.071
1.013
-1.207

.502
.812
.569

.020
1.555
4.498

.888 .931
.212 2.753
.034 .299

.348
.560
.098

2.493
13.523
.912

.692

.877

.623

.430 1.998

.358

11.153

-.256

.550

.217

.641

.774

.263

2.276

.389

.437

.792

.373 1.475

.627

3.474

.680

aThe reference category is no change. bThe standard error of predictor variables in
the model was far less than 2.0, indicating that there were no numerical problems
with predictor variables in the final model.
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Table 32
Classification Accuracy of Predictors for Clinically Meaningful Change in 6MWD
Predicted
Observed

Improved

Deteriorated

No change

Percent correct

Improved

44

4

20

64.7%

Deteriorated

11

6

21

15.8%

20

No change
Overall percentage

3

41.4%

7.2%

52
51.4%

69.3%
56.4%

history of diabetes, history of coronary artery disease, history of coronary
revascularizations, history of peripheral vascular disease, diastolic HF, beta-blocker
usage, ACE/ARBs usage, history of ICD implantation, and telemonitoring usage.
Multinomial logistic regression analysis was performed by entering variables through an
entry method into the main effects model. The category of participants with no
meaningful change in 6MW was selected as the reference category. Multinomial
regression analysis was performed on 161 participants (40 were missing data; see Table
33).
The benchmark to characterize this multinomial logistic regression model as
useful was a 25% improvement over the rate of accuracy achievable by chance alone.
The proportional by-chance accuracy rate was computed by calculating the proportion of
cases for each group (improved, deteriorated, and no change) based on the number of
cases in each group in the marginal percentages of case processing summary, as
previously described, and then squaring and summing the proportion of cases in each
group: 0.3422 + 0.193 2 + 0.466

2

.

The proportional by-chance accuracy criterion was
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Table 33
Case Processing Summary for Predictors of Clinically Meaningful Change in 6MW

N
55

34.2%

31

19.3%

No change

75

46.6%

Yes

67

41.6%

No

94

58.4%

Yes

126

78.3%

No

35

21.7%

Yes

68

42.2%

No

93

57.8%

Yes

41

25.5%

No

120

74.5%

Yes

23

14.3%

No

138

85.7%

Yes

131

81.4%

No

30

18.6%

Yes

146

90.7%

No

15

9.3%

Yes

45

28.0%

No

116

72.0%

Technology-driven disease
management

72

44.7%

Standard medical care

89

55.3%

161

100.0%

Clinically meaningful change in Improved
6MW
Deteriorated

DM-II
History of CAD
Revascularization procedures
Peripheral vascular diseases
Diastolic HF
Beta-blockers
ACE inhibitors/ARBs
lCD
Randomization

Marginal
Qercentage

Valid

40

Missing
Total

201

SUbpopulation

161 a

aThe dependent variable has only one value observed in 161 (100.0%) subpopulations.
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46.4% (1.25 x 37.1% = 46.4%). The classification accuracy rate of this model should be
greater than the proportional by-chance accuracy criteria of 46.4%.
2

The probability ofthe model's chi-square (X = 44.177, df= 24, 12 = 0.007) was
statistically significant ill. < 0.05). The null hypothesis that there was no difference
between the model without independent variables and the model with independent
variables was rejected. The existence of a relationship between the independent variables
and the dependent variable was supported (see Table 34).

Table 34
Model Fitting Information for Predictors of Clinically Meaningful Change in 6MW
Model-fitting
criteria
-2 log
likelihood

Model
Intercept only

334.875

Final

290.698

Likelihood ratio tests

Chi-square

44.177

Sig.

df

24

.007

The likelihood ratio tests for BMI, ejection fraction, beta-blocker usage, and ICD
implantation were statistically significant (2 < 0.05), suggestive of significant prediction
of clinically meaningful change in 6MW (see Table 35) BMI, LVEF, beta-blocker usage,
and ICD implantation were significant predictors for differentiating clinically meaningful
improvement in 6MW vs. no clinically meaningful change in 6MW, whereas betablocker usage was the only variable significant enough to differentiate clinically
meaningful deterioration in 6MW vs. no clinically meaningful change in 6MW (see
Table 36).
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Table 35
Likelihood Ratio Tests for Predictors of Clinically Meaningful Change in 6MW
Model-fitting
criteria

Likelihood ratio tests

-2 log
likelihood of
reduced model a

Chi-sguare

df

Intercept

2.907E2

.000

0

Age

292.934

2.236

2

.327

BMI

297.758

7.060

2

.029

LVEF

298.792

8.094

2

.017

DM-II

294.636

3.938

2

.140

History of CAD

291.213

.515

2

.773

History of
revascularizations

294.878

4.180

2

.124

History of peripheral
vascular disease
(PVD)

294.099

3.401

2

.183

Diastolic HF

293.209

2.511

2

.285

Beta-blocker usage

297.250

6.551

2

.038

ACE-I1ARBs usage

290.846

.148

2

.929

History ofICD
implantation

298.369

7.671

2

.022

Telemonitoring

291.581

.883

2

.643

Effect

Sig.

Note. The chi-square statistic was the difference in -2 log likelihoods between the final
model and a reduced model. The reduced model was formed by omitting an effect from
the final model. The null hypothesis was that all parameters ofthat effect were zero.
aThis reduced model was equivalent to the final model because omitting the effect did not
increase the degrees of freedom.
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Table 36
Parameter Estimates for Predictors of Clinically Meaningful Change in 6MW
95% confidence
interval for expb
Clinically meaningful change in
6MWa
Improved

B

SE

Wald

Sig.

EXpb

Lower
bound

Upper
bound

Intercept

8.404

3.446

5.948

.015

Age

-.048

.033

2.150

.143

.953

.894

1.016

BMI

-.091

.043

4.426

.035

.913

.838

.994

LVEF

-.057

.021

7.473

.006

.945

.907

.984

DM

.741

.429

2.992

.084

2.098

.906

4.860

CAD

-.348

.520

.447

.504

.706

.255

1.957

Revascularizations

-.862

.450

3.671

.055

.422

.175

1.020

.047

.442

.011

.915

1.048

.441

2.493

1.226

.889

1.901

.168

3.406

.597

19.445

.577

4.773

.029

.283

.091

.878

.058

.686

.007

.933

1.059

.276

4.061

ICD implantation

1.117

.466

5.748

.017

3.057

1.226

7.619

Telemonitoring

-.062

.420

.022

.882

.940

.412

2.142

2.270

3.692

.378

.539

Age

-.026

.036

.496

.481

.975

.907

1.047

BMI

.024

.042

.333

.564

1.025

.943

1.113

LVEF

-.031

.024

1.734

.188

.969

.926

1.015

DM

-.145

.516

.079

.779

.865

.315

2.378

CAD

-.007

.617

.000

.991

.993

.296

3.330

Revascularizations

-.659

.535

1.519

.218

.517

.181

1.476

-1.005

.627

2.567

.109

.366

.107

1.252

1.014

.883

1.318

.251

2.757

.488

15.567

Beta-blocker usage

-1.181

.596

3.928

.048

.307

.095

.987

ACE-I1ARBs usage

.331

.882

.140

.708

1.392

.247

7.842

-.235

.635

.138

.711

.790

.228

2.742

.394

.479

.675

.411

1.483

.579

3.794

PVD
Diastolic HF
Beta-blocker usage
ACE-I1ARBs usage

Deteriorated Intercept

PVD
Diastolic HF

ICD implantation
Telemonitoring

-1.261

aThe reference category is no change. bThe SE of predictor variables in the model was far less
than 2.0, indicating that there were no numerical problems with predictor variables in the final
model.
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The classification accuracy for clinically meaningful improvement in 6MW was
62% and for no meaningful change in 6MW, was 77%. The classification accuracy for
clinically meaningful deterioration in 6MW was 23%. The overall prediction accuracy of
this model was 62%, which was greater than that of classification accuracy by chance
alone (i.e., 46.4%; see Table 37). Therefore, this prediction model was valid to predict
clinically meaningful change in 6MW.

Table 37
Classification Accuracy for Predictors of Clinically Meaningful Change in 6MW
Predicted
Observed

Improved

Deteriorated

No change

Percent correct

Improved

34

0

21

61.8%

5

7

19

22.6%

17

0

58

77.3%

34.8%

4.3%

60.9%

61.5%

Deteriorated
No change
Overall percentage

Predictors for Clinically Meaningful Change in MLHF Total Score
Clinically relevant independent variables were selected from baseline
characteristics to predict clinically meaningful change in MLHF total score. These
variables included age, BMI, ejection fraction, history of diabetes, history of coronary
artery disease, history of coronary revascularizations, history of peripheral vascular
disease, diastolic HF, beta-blocker usage, ACE/ARBs usage, history oflCD implantation,
and telemonitoring usage. Multinomial logistic regression analysis was performed by
entering variables through an entry method into the main effects model. The category of
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participants with no clinically meaningful change in MLHF total score was selected for
the reference category.
Multinomial regression analysis was performed on 181 participants (20 were
missing data). The probability of chi-square statistic for the model with the variables was
not statistically significant and did not meet the model-fitting criteria. The independent
variables with low chi-square static values were dropped from the model, and the reduced
model (meeting the fitting criteria) was deduced. The reduced model, using age, history
of diabetes, history of coronary revascularization procedures, and telemonitoring and
meeting the model-fitting criteria (X2= 16.34, df= 8,12 = 0.037) was performed on 201
participants (none were missing data; see Table 38).
The benchmark to characterize this multinomial logistic regression model as
useful was a 25% improvement over the rate of accuracy achievable by chance alone.
The proportional by-chance accuracy rate was computed by calculating the proportion of
cases for each group (improved, deteriorated, and no change) based on the number of
cases in each group in the marginal percentages of case processing summary, as
previously described, and then squaring and summing the proportion of cases in each
group: 0.2842 + 0.338 2 + 0.378 2 . The proportional by-chance accuracy criterion was
42.25% (1.25 x 33.79% = 42.25%). The classification accuracy rate ofthis model should
be greater than the proportional by-chance accuracy criteria of 42.25% (see Table 39).
Though the model fit well, there were no statistically significant individual predictors for
clinically meaningful change in MLHF total score (see Tables 40 & 41).
The classification accuracy for clinically meaningful improvement in MLHF total
score was 23% and for no meaningful change in MLHF total score, was 58%. The
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Table 38
Case Processing Summary for Predictors of Clinically Meaningful Change in MLHF
Total Score
Marginal
Qercentage

N

Clinically meaningful
improved
change in MLHF total score deteriorated
DM
Revascularization
procedures
Randomization

no change
yes
no
yes
no
Technology driven disease
management
Standard medical care

57

28.4%

68

33.8%

76
85
116
86
115

37.8%
42.3%
57.7%
42.8%
57.2%

95

47.3%

106
52.7%
Valid
201
100.0%
Missing
0
Total
201
Subpopulation
129a
aThe dependent variable had only one value observed in 93 (72.1 %) subpopulations.

Table 39
Model Fitting Information for Predictors of Clinically Meaningful Change in MLHF
Total Score
Model-fitting
criteria
Model

-2 log
likelihood

Intercept only

360.376

Final

343.992

Likelihood ratio tests
Chi-square
16.384

106

df

Sig.

8

.037

Table 40
Likelihood Ratio Tests for Predictors of Clinically Meaningful Change in MLHF Total
Score
Model-fitting criteria

Likelihood ratio tests

-2 log likelihood of
reduced model

Effect

Chi-square

Sig.

df

3.440E2
.000
Intercept
0
Age
349.117
5.125
2
.077
4.506
2
.105
DM
348.498
Telemonitoring
348.407
4.415
2
.110
aThis reduced model was equivalent to the final model because omitting the effect did not
increase the degrees of freedom.
Table 41
Parameter Estimates for Predictors of Clinically Meaningful Change in MLHF Total
Score
95% confidence
interval for expb
Clinically meaningful change
in MLHF total scorea
Improved

Deteriorated

Intercept

B

SE

-1.950 1.975

Wald

Sig.

.975

.323

Expb

Lower
bound

Upper
bound

Age

.018

.025

.496

.481

1.018

.969

1.069

Diabetes mellitus

.640

.368

3.030

.082

1.897

.923

3.899

Revascularization

-.319

.366

.761

.383

.727

.355

1.488

Telemonitoring
Intercept

.417 .365
2.459 1.764

1.304
1.944

.254
.163

1.517

.742

3.100

Age

-.035

.023

2.330

.127

.966

.924

1.010

Diabetes mellitus

-.101

.361

.078

.780

.904

.445

1.835

Revascularization

-.691

.358

3.736

.053

.501

.248

1.010

.729

.353

4.276

.039

2.073

1.039

4.138

Telemonitoring

aThe reference category is no change. bThis parameter is set to zero because it is
redundant.
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Table 42
Classification Accuracy for Predictors of Clinically Meaningful Change in MLHF Total
Score
Predicted
Observed
Improved
Deteriorated
No change
Overall percentage

Deteriorated

Improved

No change

Percent correct

13

14

30

22.8%

8

29

31

42.6%

14

18

44

57.9%

17.4%

30.3%

52.2%

42.8%

classification accuracy for clinically meaningful deterioration in MLHF total score was
43%. The overall prediction accuracy of this model was 42.8%, which was greater than
that of classification accuracy by chance alone (i.e., 42.28%; see Table 42). Therefore,
this prediction model was valid to predict clinically meaningful change in MLHF total
score.
Clinical Outcomes
Technology-driven HF management was shown to reduce the number of days of
hospitalization from HF as the primary diagnosis, the number of days of hospitalization
from other cardiovascular causes, the number of Medicare claims for inpatient
admissions, the number deaths from all causes, the number of deaths from all
cardiovascular causes, and the number of deaths from HF, compared to standard care.
However, these differences were not statistically significant. Technology-driven HF
management showed increases in the number of days of hospitalizations from
noncardiovascular causes, number of ER visits, number of clinic visits for all causes,
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number of clinical visits for all cardiovascular causes, and number of clinical visits from
HF ill < 0.05) and increased cost of clinic claims (12 < 0.05).
Therefore, technology-driven HF management reduced the number of days of
hospitalization but increased the number of outpatient visits for all cardiovascular causes
or HF. The standard care group had a higher number of days of hospitalization and a
lower number of outpatient visits from cardiovascular causes or HF. Further analysis by
combining these end points and deducing cost effectiveness was beyond the scope of this
dissertation. The primary end points of the HCFA Demonstration Project were separately
analyzed by primary investigators of the project (see Table 43).
Mortality
Out of201 total patients who were included in final analysis, 6 out of95 (6.3%)
in the technology-driven HF management group and 10 out of 106 (9.4%) in the standard
care group died from any cause (OR: 0.647,95%; CI: 0.226-1.854). In terms of
cardiovascular deaths, 5 out of95 (5.3%) in the technology-driven HF management
group and 9 out of 106 (8.5%) in the standard care group died from cardiovascular causes
(OR: 0.599,95%; CI: 0.193-1.854). Finally, 3 out of95 (3.2%) patients in the
technology-driven HF management group and 5 out of 106 (4.7%) in the standard care
group died from HF (OR: 0.659,95%; CI: 0.153-2.833). Technology-driven HF
management showed a trend toward decreasing all causes of mortality, mortality from all
cardiovascular causes, and mortality from worsening ofHF (see Figures 11-13).
However, the incremental impact of adding a telemonitoring system to the standard of
care was not statistically significant (p> 0.05).
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Table 43
Clinical End Points for Technology-Driven Management GrouQ vs. Standard Care GrouQ
Treatment group
N
Days of hospitalization (all
causes)
Days ofhospitaiization (CHF
primary diagnosis)
Days of hospitalization
(other CVD primary
diagnosis)
Days of hospitalization
(noncardiovascular primary
diagnosis)
In-patient claims
ER claims
Clinic visits (all causes)
Clinic visits (CHF primary
diagnosis)
Clinic visits (CVD primary
diagnosis)
Deaths from all causes
Deaths from all
cardiovascular causes
Deaths from HF
Cost of in-patient claims
Cost of ER claims
Cost of clinic claims

Sum Mean

Control group
N

!-test

Sum

Q:

Mean value
2.48 0.30

95

358

3.77

106

263

95

116

1.22

106

158

1.49

0.69

95

172

1.81

106

195

1.84

0.97

95

186

1.96

106

68

0.64

0.78

95
95
95
95

68
37
290
81

0.72
0.39
3.05
0.85

106
106
106
106

90
25
87
21

0.85
0.24
0.82
0.20

0.41
0.10
0.00
0.01

95

176

1.85

106

45

0.42

0.00

95
95

6
5

0.06
0.05

106
106

10
9

0.09
0.08

0.41
0.36

95
95
95
81

3
620769
7437
31512

0.03
6534
78
389

5
106
106 675596
106
7882
90
10380

0.05
6373
74
115

0.57
0.93
0.89
0.01
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Figure 11. Kaplan-Meier Curve for Death from all Causes in 6 months.
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CHAPTER V
DISCUSSION
Summary of Results
This sub study was conducted based on a multicentered, randomized, phase III
clinical trial of Medicare beneficiaries who were previously hospitalized with HF
(NYHA Class II-IV) to evaluate the combined clinical and economic outcomes of
adding a technology-driven HF monitoring system to standard HF management. The
effect of technology-driven HF monitoring on functional capacity and QOL was
evaluated by measuring the magnitude and direction of change at a 6-month follow-up.
Traditional statistical techniques were translated to derive novel refined methods in order
to define clinically meaningful difference in terms of functional capacity and QOL. The
agreement between existing objective methods of assessing severity ofHF in terms of
NYHA class and 6MWD was tested. The clinically relevant factors predictive of
clinically meaningful change in functional capacity and QOL were also deduced. Finally,
the clinical outcomes of technology-driven HF management vs. standard care groups at
the end of 6 months were compared.
Importance of Clinically Meaningful Change
Traditionally, treatment effects are evaluated by comparing changes resulting
from the treatments under investigation and evaluating the statistical significance of that
difference. In clinical trials, treatment effects often show statistically significant
difference, but very little attention is paid to clinical significance. Statistical significance
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is a function of the alpha level, the variance of the outcome measure, the
magnitude of the difference, and the sample size. Clinicians often are interested in the
variability of responses between and within groups. However, traditional methods are
very limited in terms of determining the variability of response within a group due to lack
of translation of traditional statistical methods to precise and refined novel statistical
methods for determining clinically meaningful difference.
Need for Adjustment of Regression to the Mean
If patients, particularly those with extreme values, are repeatedly measured after
treatment, the repeat measurement will be closer to the mean of the whole population
than the initial measures were. In clinical trials, this phenomenon is often interpreted as
showing the effect of the intervention or treatment; clinical investigators often assume
that ifthey observe differences in baseline measurements among subjects, they can take
the difference between the pre- and post-intervention/treatment values as the outcome
value. However, it is incorrect to do so because imbalances at the baseline values will be
reversed due to RTM. For example, subjects with a low degree of impairment at baseline
will show less improvement, and subjects with a higher degree of impairment at baseline
will show greater improvement.
In this study, functional capacity and QOL were repeatedly measured in terms of
6MWD or 6MW and MLHF scores on same subjects before and after treatment. At a 6month follow-up, it was found that RTM was statistically significant, which meant that
natural variation due to repeat data collection gave the appearance of real change. Hence,
in clinical trials, if functional capacity or QOL is measured pre and post test, RTM must
be estimated; otherwise, treatment effects will be overestimated and biased. If R TM is
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significant, then RTM should be adjusted using the E-N method to determine true change
from baseline.
Clinically Meaningful Change in Functional Capacity and Quality of Life
In this study, clinically meaningful difference in functional capacity and QOL was
estimated after a 6-month follow-up after adjusting for RTM effects. The change in
functional capacity in terms of6MWD by 42 m (39 m-42 m) or 6MW by 3668 kg/m
(3063 kg/m-3820 kg/m) and in QOL in terms ofMLHF total score by 6.0 (5.0-7.0),
physical dimension score by 4.0 (3.0-4.0), and emotional dimension score by 2.0 (2.03.0) from baseline was determined as either clinically meaningful improvement or
deterioration.
Effect of Technology-Driven Heart Failure Management on Functional Capacity
Addition oftwice-daily home telemonitoring of weight and HF symptoms to
standard care for Medicare beneficiaries with chronic HF did not result in clinically
meaningful change in functional capacity after 6 months. The null hypothesis failed to be
rejected and the alternative hypothesis failed to be accepted. After stratification by
NYHA class, it was found that technology-driven HF management retarded the change
from baseline for a slightly higher proportion of patients in NYHA Class II than in
Classes III and IV; a slightly higher proportion of patients in NYHA Classes III and IV
than in Class II showed clinically meaningful improvement. In the standard care group, a
slightly higher proportion of patients in NYHA Class II showed improvement and a
slightly higher proportion of patients in Classes III and IV showed retarded change.
Therefore, technology-driven HF management improved functional capacity for a slightly
higher proportion of patients in NYHA Classes III and IV and stabilized functional
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capacity for a slightly higher proportion of patients in NYHA Class II. However, none of
these effects reached statistical significance at a 6-month follow-up. Therefore, there is
no clinically meaningful incremental benefit in functional capacity from adding
technology-driven HF monitoring to standard care.
Effect of Technology-Driven Heart Failure Management on Quality of Life
Addition of twice-daily home telemonitoring of weight and HF symptoms to
standard care for Medicare beneficiaries with chronic HF did not show clinically
meaningful change in QOL. The null hypothesis failed to be rejected, and the alternative
hypothesis failed to be accepted. The standard care group showed retarded change, and
the technology-driven HF management group showed clinically meaningful deterioration
in a greater proportion of patients than the standard care group. After stratification by
NYHA class, these trends persisted irrespective of NYHA class. However, none of these
effects reached statistical significance. Therefore, there is no clinically meaningful
benefit in QOL from adding technology-driven HF monitoring to standard care. Rather,
technology-driven HF monitoring may be counterproductive and lead to deterioration in
QOL, possibly by interfering with the daily routine of patients. Hence, patients may
perceive technology-driven HF monitoring as impairing their QOL.
Effect of Technology-Driven Heart Failure Management on Clinical Outcomes
Technology-driven HF management did not show any statistically significant
benefit for reducing the number of Medicare claims for inpatient admissions; the number
of days of hospitalization from HF and other cardiovascular causes; and the number of
deaths from all causes, all cardiovascular causes, and HF at the end of a 6-month followup. However, there was a statistically significant increase in the number of outpatient
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clinic visits for all causes, all cardiovascular causes, and HF and the cost of Medicare
claims for clinic visits at a 6-month follow-up. After 6 months, technology-driven HF
management significantly increased resource utilization of outpatient care, and there was
no statistically significant reduction in resource utilization of inpatient care when
compared to standard care.
The intervention group received twice-daily monitoring of weight and symptoms
by telemonitoring center nurses, which could have led to sending alerts to physicians
early in the course of HF decompensation. A substantial proportion of the participants
(25%) reported receiving care from a primary care physician without a cardiologist on
board. In addition, the cardiologists who provided care to the participants may not have
had training in advanced HF management. For these reasons, patients may have
overutilized outpatient clinic visits. Participants in the standard care group did not report
this type of communication between physician and patient, probably because the
progression of the disease was recognized in the later part of decompensation process.
Therefore, this group experienced more hospitalizations and total days of
hospitalizations; however, these effects didn't reach statistical significance. At the same
time, the standard care group experienced a statistically significant reduction in outpatient
clinic visits at the end of 6 months compared to the technology-driven HF management
group.
Agreement Between Objective Assessment of Functional Capacity and Classification of
Heart Failure NYHA Criteria
To determine a patient's NYHA class, clinicians ask patients about their HF
symptoms and the effect on exertion (i.e., how far they can walk before symptom onset).
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However, there is no consistent method for determining NYHA functional class. The
method of assessing NYHA class is arbitrary, and intraoperator variability is 66% (R.
Claire et al., 2007). As mentioned earlier, 6MWD is a simple, cost-effective means of
clinically assessing the functional capacity of patients with cardiac and pulmonary
diseases. The NYHA system and 6MWD are regularly used as outcome measures in
clinical trials and are even included in HF management guidelines ("ACC/AHA
Guidelines," 2009). Hence, the agreement between these two functional classifications
was examined.
There is a lack of agreement between objective assessment of NYHA functional
class and objective measurement of functional capacity (6MWD). The correlation
coefficient between these two outcome measures was very poor because either patients
are under- or over-reporting functional capacity to their physicians or physicians are
misinterpreting patient class compared to objectively measured values. Still, 6MWD
may not be the single best indicator of severity of HF among groups of patients of
different ages, genders, BMIs, and comorbid conditions. This lack of consistency
between NYHA class and 6MWD suggests the need to develop novel classification
methods by designing norm-referenced equations comprising age, gender, BMI,
comorbid conditions, and symptoms and signs of HF.
Prediction of Change in Quality of Life by Change in Functional Capacity
In this study, change refers to clinically meaningful change, not statistical change
from baseline. The sensitivity and specificity of change in functional capacity to predict
change in QOL was low, and Spearman correlation coefficients were very weak.
Clinically meaningful improvement in functional capacity to predict clinically
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meaningful improvement in QOL and clinically meaningful deterioration in functional
capacity to predict clinically meaningful deterioration in QOL, and vice versa, were
estimated. If there was improvement in functional capacity (6MWD), the probability of
improvement in QOL (MLHF) was 56%. However, if there was improvement in QOL,
the probability of improvement in functional capacity was only 44%. If there was
deterioration in functional capacity, the probability of deterioration in QOL was 35%.
However, ifthere was deterioration in QOL, the probability of deterioration in functional
capacity was 55%.
The probability of change in functional capacity was more responsive to
deterioration in QOL than probability of improvement in QOL: If there was no change in
functional capacity, the probability of no change in QOL was 35%. If there was no
change in QOL, the probability of no change in functional capacity was 31%. If the
functional capacity was measured in terms of 6MW, it had similar probabilities of
predicting improvement and deterioration patterns. But, if there was no change in
functional capacity, the probability of no change in QOL was 53%. Ifthere was no
change in QOL, the probability of no change in functional capacity was 43%, which was
8% higher than that of no change in 6MWD.
Overall, the change in functional capacity is not a good predictor of similar
directional change in QOL and vice versa. Therefore, if a clinician sees improvement in
functional capacity, the probability of improvement in QOL is 56%. If there is
deterioration in QOL, the probability of deterioration in functional capacity is 55%. In all
other cases, it is difficult to predict the direction of change in QOL with respect to change
in functional capacity and vice versa.
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Predictors of Change in Physical and Emotional Dimension Scores by Change in
Functional Capacity
Ifthere is change in functional capacity (6MWD), the probability of similar
directional change in physical dimension score is 69% for improvement, 35% for
deterioration, and 46% for no change; the probability of similar directional change in
emotional dimension score is 100% for improvement, 64% for deterioration, and 45% for
no change. If there is a change in physical dimension score, the probability of similar
directional change in functional capacity is 30% for improvement, 31 % for deterioration,
and 71 % for no change. If there is a change in emotional dimension score, the
probability of similar directional change in functional capacity is 12% for improvement,
17% for deterioration, and 95% for no change.
In summary, change in functional capacity is a poor predictor of change in total
QOL; however, functional capacity shows good predictive patterns for change in physical
and emotional components of QOL. Improvement in functional capacity increases the
probability of improvement in physical dimension score but not vice versa. Change in
functional capacity increases the probability of similar directional change in emotional
dimension score but not vice versa. Surprisingly, change in functional capacity better
predicts change in emotional dimension score than physical dimension score. Similar
patterns were observed with 6MW. It is not surprising that improvement in functional
capacity predicts improvement in physical dimension score. Surprisingly emotional
scores are influenced by physical endurance. The sense of accomplishment in improving
functional capacity may improve patients' self esteem by providing them with positive
feedback, which in tum improves the emotional dimension score.
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Perception of QOL involves a complex interplay of multidimensional indices of
life. A change in physical, emotional, or socioeconomic indices that leads to a change in
the suhscore of one dimension does not always translate into change in total score or
functional capacity due to fluctuations in other item scores. Therefore, change in
functional capacity is a poor predictor of change in total QOL score and vice versa.
Specificity and negative predictive value of change in functional capacity are far better
than sensitivity and positive predictive values to predict similar directional change in total
QOL and its components.
Predictors of Clinically Meaningful Change for Functional Capacity
BMI, LVEF, type-2 diabetes, and beta-blocker usage are statistically significant
predictors of clinically meaningful change in functional capacity (6MWD). BMI and
LVEF are inversely related to improvement in functional capacity (i.e., the regression
coefficients are negative). As BMI increases, improvement in functional capacity is less
likely. As LVEF improves, functional capacity improves initially; once functional
capacity reaches the ceiling effect, improvement in functional capacity is less likely.
Subjects with type 2 diabetes mellitus (OR 2.281,95% ofCI: 1.019 to 5.103) are
more likely to improve in functional capacity. Diabetes itself doesn't improve functional
capacity, but additional diabetics-related care processes might contribute to improvement
in functional capacity. Subjects who use beta-blockers (OR 0.289, 95% of CI: 0.094 to
0.888) are less likely to show improvement and less likely to show deterioration (OR
0.299,95% ofCI: 0.98 to 0.912) in functional capacity. Therefore, beta-blockers playa
significant role in stabilizing functional capacity.
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BMI, LVEF, and beta-blocker usage show similar significant predictive patterns
for predicting clinically meaningful change in 6MW. ICD implantation is also a
significant predictor of functional capacity (6MW). Subjects with ICD implantation
show clinically meaningful improvement in functional capacity (OR 3.06, 95% of CI:
1.23 to 2.14).
Predictors of Change in Quality of Life
The reduced regression model, which contained the independent variables of age,
type 2 diabetes mellitus, revascularization procedures, and technology-driven HF
monitoring, satisfied model fit criteria. None of the independent variables surfaced as
significant individual predictors of clinically meaningful improvement in QOL (MLHF
score), whereas technology-driven HF monitoring was a statistically significant predictor
of clinically meaningful deterioration in QOL. Twice-daily recording of weight,
answering automated questions about symptoms, and receiving telephone calls from
Alere nurses may interfere with the daily routines of patients with HF, who may perceive
technology-driven HF monitoring as impairing their QOL.
Comparison of Existing Studies
It has to be acknowledged that to date the majority of studies that test telephonic

support (Riegel et aI, 2002; Laramee, 2003; DeBusk, Miller and Parker, 2004; Gesica
Inv, 2005; Riegel et aI, 2005) and vital sign monitoring (deLusignan, 2001; Woodend et
aI, 2003; Capomolla et aI, 2004) have not shown a mortality benefit in patients with
chronic heart failure. Only a few studies have shown that telephonic support (Cleland et
aI, 2005) and vital sign monitoring (Cleland et aI, 2005; Goldberg et aI, 2002) reduced
mortality. The difference in mix of patients and provider populations, geographical
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settings, treatment modalities, and monitoring strategies might explain different outcomes
in different studies.
Telephonic support and vital sign monitoring are two different strategies to
monitor HF patients. Cleland (2005) and Goldberg (2002) showed there was a significant
absolute reduction in mortality by 10.4% and 16% respectively through electronic
monitoring of vital signs and symptoms. In our study the absolute reduction in mortality
was only 3% which is not statistically significant. In Cleland's (2005) study primary care
physicians delivered standard care for all heart failure patients. In the WHARF
(Goldberg et aI, 2002) trial, patients were sicker with more advanced heart failure
(NYHA class III and IV) than in our sample and care was provided by cardiologists with
advanced training in heart failure management. In our study 31 % of patients were NYHA
class II and a substantial proportion of patient care was provided by cardiologists without
advanced training in heart failure or by primary care physicians without a cardiologist on
board. However, the proportion of patients on beta-blockers and ACE-I1ARBs in our
study was greater than in the WHARF trial (Goldberg et aI, 2002) suggesting more
widespread acceptance of the American College of Cardiology and the American Heart
Association guidelines. Our study'S patient population having less advanced heart failure
would predict much lower mortality than observed in the WHARF trial and hence less
opportunity for electronic monitoring to reduce the absolute death rate.
Strengths of the Study
The WHARF trial (Goldberg et aI., 2002) was the first multi-centered, prospective
trial conducted for patients with advanced HF (NYHA Classes III and IV). Researchers
concluded that there was a significant mortality benefit from home-based telemonitoring
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with a nurse-staffed call center (Goldberg et aI., 2002). At the end of 6 months, 18.4% of
participants in the standard care group and 8.0% of those in the telemonitored group died
(Goldberg et aI., 2002). Thus, there was a 56.2% relative risk reduction in mortality for
the telemonitored group of patients with advanced HF (Goldberg et al., 2002). However,
there was no significant difference between the two groups with respect to length of stay,
number of hospitalizations, and utilization of resources (Goldberg et aI., 2002).
The results of the WHARF study were attributable to patients with advanced HF
(NYHA Classes III and IV) but not to NYHA Class II patients because the study was
conducted for NYHA class III and IV patients only (Goldberg et aI., 2002). Only
cardiologists with special training in advanced HF management provided care for patients
recruited for the study (Goldberg et aI., 2002). It is possible that these cardiologists better
utilized the data generated through technology-driven HF monitoring than primary care
physicians would have. Hence, reproducing a similar benefit in a real-world clinical
setting may not be feasible because most HF care is provided by cardiologists without
training in advanced HF management and primary care physicians without training in
cardiology or without a cardiologist on board.
The HCF A HF Demonstration Project was conducted for Medicare beneficiaries
classified as NYHA Class II-IV. Therefore, the findings of the sub-study are attributable
to elderly patients with HF who belong to NYHA Class II-IV. HF management was
provided by cardiologists with or without training in advanced HF management or by
primary care physicians with or without cardiologist on board. Therefore, the findings of
the sub-study are attributable to the current real-world clinical setting of HF management.

124

In the WHARF trial, due to differential drop-outs between groups (including
death and drop-outs), the baseline QOL scores were carried forward to compare scores
for all patients at 6 months, which might have introduced statistical bias (Goldberg et aI.,
2002). In the current study, patients who dropped out were excluded from the analysis
and were compared with participants who were included in the analysis. Patients who
died from HF or cardiovascular causes were included in the clinically meaningful
deterioration group and given extremely worsened scores of QOL and functional capacity
to minimize bias.
Other HF monitoring studies have used traditional distribution-based statistical
methods and placed importance on statistical significance rather than clinical significance
(Goldberg et aI., 2002). The current study addressed the importance ofRTM and
adjusted R TM while measuring true change from the baseline. Also, the importance of
measuring clinically meaningful change from the baseline, instead of using traditional
methods of assessing statistically significant difference, was addressed. Traditional
statistics were translated into more refined methods to provide meaningful information to
clinicians on the effect of technology-driven HF management vs. standard care on
functional capacity and QOL of patients with HF, clinically meaningful change, and
factors affecting the degree of change and direction of change at the end of 6 months.
Limitations of the Study
The study was conducted for Medicare beneficiaries over 65 who were
hospitalized for HF less than 1 year ago (i.e., NYHA Class II-IV). Therefore, the
findings may not be attributable to patients with HF who are younger than 65. Patients
were randomized from four geographic and hospital settings. The findings may not be
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attributable to other centers where HF care is provided primarily by cardiologists,
especially those with special training in advanced HF management.
Because a substantial proportion of patients (~25%) did not have a cardiologist on
board and primary care physicians provided all of their HF management, there was
overutilization of services and less efficient utilization of HF monitoring alerts.
Physicians and patients were not blinded to the technology-driven HF monitoring system;
hence, there was a likelihood of introducing treatment bias. Drop-outs, lost-to-follow
cases, and missing data were unexpectedly high, and the compliance rate was low. The
sub study was limited to a 6-month follow-up. Hence, the long-term effects of
technology-driven HF monitoring are not known.
Post-Hoc Power Analysis
Post-hoc power is directly proportional to the effect size and inversely
proportional to the 12-value. Ifthe effect size is trivial or the 12-value is large, then the
post-hoc power will be low. If the 12-value is larger than 0.05, then the post-hoc power is
likely to be less than 50%. Therefore, calculation of the 12-value is not meaningful in the
case of a negative clinical trial. Several authors have mentioned the inappropriateness of
post-hoc power for negative end points and have suggested the use of confidence
intervals instead of post-hoc power (Detsky & Sackett, 1985; Goodman & Berlin, 1994;
Smith & Bates, 1992). Post-hoc power can provide meaningful information for positive
end points (Detsky & Sackett, 1985; Goodman & Berlin, 1994; Smith & Bates, 1992).
In this study of change in functional capacity and QOL, there was no statistically
significant clinically meaningful difference between the telemonitored vs. standard care
groups. Based on the direction of change in functional capacity and QOL, the sample
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was grouped into three groups: clinically meaningful improvement, deterioration, and no
change. Confidence intervals for X2 static for above frequency distributions were
calculated. The 95% confidence interval for the Chi-squared distribution with two
degrees of freedom was 0.05-7.38. Chi-square statistics for distributions for clinically
meaningful change in 6MWD (0.256), 6MW (0.131), MLHF score (3.877), physical
dimension score (0.309), and emotional domain score (0.762) for the treatment vs.
standard care group fell inside the 95% confidence interval.
Post-hoc power analysis was performed for multinomial logistic regression
models and other clinical outcomes with statistical significance. Post-hoc power of the
prediction model to predict clinically meaningful change in functional capacity measured
in terms of6MWD (alpha = 0.05, number of predictors in the model = 12, R2= 0.236,
valid sample size = 181) and 6MW (alpha = 0.05, number of predictors in the model =
12, R2= 0.240, valid sample size = 161) was 99.9%. Post-hoc power of the model to
predict clinically meaningful change in QOL measured in terms ofMLHF score (alpha =
0.05, number of predictors in the model = 4, R2= 0.201, valid sample size = 201) was
92%. Post-hoc power to detect mean difference between the telemonitored vs. standard
care groups for the number of clinic visits for all causes, for HF, and for other
cardiovascular causes was 97%, 65%, and 95%, respectively. The post-hoc power to
detect mean difference in cost of clinic claims (treatment group vs. standard care group)
was 65%. Other well-powered studies are needed to further investigate underpowered
clinical endpoints.
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Conclusions and Implications
1. Both the technology-driven HF management and standard care groups showed
significant improvement in functional capacity and QOL from baseline after 6
months. However, the differences between groups were not statistically
significant. Therefore, there is no meaningful benefit in terms of functional
capacity and QOL from the addition of home telemonitoring systems to standard
care. In fact, home telemonitoring systems may deteriorate QOL by interfering
with patients' daily routine activities. In addition, there was a statistically
significant increase in the total number of clinic visits, the number of clinic visits
for HF, and the number of visits for other cardiovascular causes. In turn, there
was a statistically significant increase in the cost of clinic (Medicare) claims.
2. In clinical trials, if outcomes are measured pre and post test, RTM must be
estimated; otherwise, treatment effects will be overestimated and biased. If RTM
is significant, then it should be adjusted to determine true change from baseline.
3. In clinical trials, investigators should focus on measuring clinically meaningful
treatment effects rather than statistically significant difference. In this study,
clinically meaningful change in functional capacity and QOL were defined
according to often-used outcome measures in HF research. The change in
functional capacity in terms of6MWD by 42 meters (39 m-42 m) or 6MW by
3668 kg/m (3063 kg/m-3820 kg/m) and QOL in terms ofMLHF total score by
6.0 (5.0-7.0), physical dimension score by 4.0 (3.0-4.0), emotional dimension
score by 2.0 (2.0-3.0) from baseline were determined to be either clinically
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meaningful improvement or deterioration based on the direction of change for
elderly patients with chronic HF.
4. Change in functional capacity is a good predictor of change in emotional
dimension score and a fair predictor of change in physical dimension score but
not predictive of change in overall QOL. If clinicians target improvement in
functional capacity, they can improve the emotional component and, to a fair
extent, the physical component, but not vice versa. Striving for clinically
meaningful improvement in functional capacity may be a clinically meaningful
strategy for dealing with depression in patients with chronic HF.
5. BMI, LVEF, beta-blocker usage, and ICD implantation are the best clinically
relevant predictors of change in functional capacity. Strategies should be targeted
to decrease BM! and improve cardiac index, rather than focusing on LVEF to
improve functional capacity. Beta-blockers stabilize functional capacity, and ICD
implantation improves functional capacity. There are no best predictors of
improvement in QOL.
6. There is a lack of agreement between objective assessment ofNYHA functional
class and objective measurement of functional capacity (6MWD). The correlation
coefficient between these two outcome measures is very poor. Utilization of
NYHA class change as an outcome measure in clinical trials for measuring
treatment effect may lead to over- or under-estimation.
Future Directives for Research
Due to lack of consistency and a high degree of operator variability when
classifying patients with HF using the NYHA method, there is an imminent need for
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development of novel classification methods by designing norm-referenced equations
comprising clinical parameters predictive of cardiac function or index. More explorative
research should be performed to identify diabetic care processes that might show
clinically meaningful improvement in functional capacity for the diabetic subset of
patients with HF. More aggressive and frequent monitoring of patients appears to be
counterproductive and to lead to noncompliance, frequent drop-outs, and loss to follow
up.
Call center nurses were not authorized to independently optimize medications,
even in consultation with a cardiologist or primary care physician. Therefore, instead of
twice-daily monitoring by call center nurses, less frequent home monitoring by healthcare
personnel trained in cardiology who are authorized to perform optimization/adjustment of
medications either independently or in consultation with a cardiologist might lead to
better resource utilization and reduction ofER visits, outpatient clinic visits, and inpatient
hospitalizations. On the other hand, if standard of care is provided while adhering to HF
guidelines and closely monitoring HF clinic follow-ups, then there may not be room for
further clinically meaningful benefit through home telemonitoring.
Analysis of combined clinical endpoints and costs should be performed to
determine the benefits of technology-driven HF management and HF monitoring
strategies. Further analysis should be conducted to evaluate efficient utilization of
information gathered through technology-driven HF monitoring and subsequent resource
utilization by primary care physicians vs. cardiologists with and without advanced
training in HF in providing HF care.
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APPENDIX
GLOSSARY!

ACE-I: Angiotensin converting enzyme inhibitors, a class of medications that

inhibit angiotensin converting enzyme
Angina: Angina is chest pain that is due to an inadequate supply of oxygen to the

heart muscle
Beta-blockers: A class of medications that block beta-adrenergic substances such

as adrenaline (epinephrine), a key agent in the "sympathetic" portion of the autonomic
nervous system and activation of the heart muscle
Blood Pressure: Pressure of the blood within the arteries
BUN: Blood urea nitrogen, measures primarily the urea level in blood
Clinic visit: Refers to outpatient care at physician's office
Cohort: In a clinical trial, a group of study subjects or patients
Congestive Heart Failure: A condition in which the heart's function as a pump

is inadequate to meet the body's needs
Coronary Angiography: Accurate method for evaluating and defining coronary

artery disease (CAD)

1. Adapted from HCFA Heart Failure Demonstration Project protocol, pp. 71-77.
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Creatinine: Creatinine is produced from creatine, a molecule of major
importance for energy production in muscles
Death due to Non-cardiovascular causes: Death not due to any cardiac or
vascular events
Death due to Progressive Heart Failure: Death preceded by worsening signs
and symptoms of heart failure and/or circulatory collapse due to pump failure in the
absence of acute myocardial infarction
Death due to other Cardiac Causes including Vascular Causes: Death due to
other cardiac causes, such as non-sudden arrhythmic death, due to vascular events such as
stroke, pulmonary embolus, ruptured aneurysm, etc.
Diastolic Dysfunction: Abnormal relaxation pattern of the left ventricle
Echocardiography: A diagnostic test, which uses ultrasound waves to make
images of heart muscles, valves and other internal structures. It measures the function of
heart and its structures
Ejection Fraction: The proportion of blood that is pumped out of a filled
ventricle with each heart beat
Emergency room visit (ER): Refers to outpatient care at emergency room, not
considered as hospitalization
Fatal Myocardial Infarction: Death as a result of an autopsy - verified
myocardial infarction or death before hospital discharge from a hospital - verified acute
myocardial infarction
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HCFA: The health care finance administration, the part ofthe US Department of
Health and Human Services (HHS) that is responsible for administering Medicare and
Medicaid
Hospitalization: Refers to inpatient admission to hospital, either overnight stay

or prolonged stay
Functional Capacity: Functional capacity refers to the performance of, or the

capacity to perform, regular daily activities
Morbidity: Illness or disease
Mortality: It refers to a fatal outcome, death
Quality of Life: A state of complete physical, mental, and social well-being and

not merely the absence of disease or infirmity
Six Minute Walk Distance: Distance that a patient can quickly walk on a flat,

hard surface in a period of 6 minutes
Six Minute Work: The product of 6-minute walk distance multiplied by the

weight of the patient: 6-min walk distance (in meters) x body weight (in kilograms)
Sudden Cardiac Death: Death, or irreversible deterioration leading to death,

occurring without warning or within one hour of symptoms (unless it is the result of
circulatory collapse due to pump failure or fatal myocardial infarction or other well
defines cardiac, vascular or non-cardiac causes. Sudden cardiac death will be further
categorized as due to brady-arrythmia, ventricular tachycardia, ventricular fibrillation,
electromechanical dissociation, or unknown cause of death
Systolic Dysfunction: Impairment of forward pumping function of the heart
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